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Abstract  
Helicobacter pylori is a bacterium capable of surviving and infecting a healthy human stomach 
and it is estimated that infect more than a half of world population. Despite of being almost always 
asymptomatic, in some cases, the infection can evolve to several gastric disease as chronic gastritis, 
peptic ulcers, gastric cancer and MALT lymphoma. Vaccination against H. pylori is a promising 
option due to emerging problems of antibiotics treatment. It is thought that oral immunization could be 
a good approach for a more effective protection against infections by H. pylori, creating a first line of 
defense in mucosal surfaces. Chitosan nanoparticles are a suitable vehicle for oral vaccines delivery 
due to its immunogenic and mucoadhesive properties, protecting the DNA and allowing high levels of 
transfected cells. Thus, this work aims to evaluate a new pDNA- and recombinant protein-based 
vaccine, with multi epitopes of different H. pylori antigens. Following production and purification of 
plasmid DNA and recombinant proteins, vaccines were formulated for oral and intramuscular 
administration with the antigens encapsulated with chitosan nanoparticles.  
The type of immune response induced and the effectiveness of protective immunity elicited 
were assessed by ELISA, through analysis of specific IgGs, mucosal SIgA and cytokines levels 
produced by immunized BALB/C mice. When give by the intramuscular route, the formulated pDNA 
and recombinant protein-based vaccines efficiently stimulated the production of specific IgG2a and 
IgG1, which is supported by cytokines levels, revealing a better and balanced systemic immune 
response than oral immunizations. Nevertheless as expected, oral immunizations with either pDNA 
vaccines or recombinant protein revealed high levels of SIgA, showing to be effective in gastric 
mucosal immunization for a more protective immune response, contrasting with intramuscular 
immunizations which did not induce SIgA. 
 The immunization results showed that both pDNA and recombinant proteins vaccines 
encapsulated with chitosan nanoparticles are good candidates for the development of a future vaccine 
to prophylactic and therapeutic use to improve the eradication of H. pylori infections. 
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Resumo 
 
Helicobacter pylori é uma bactéria capaz de sobreviver e infectar o estômago humano saudável e 
estima-se que mais de metade da população mundial esteja infectada. Apesar de, na sua maioria, estas 
infecções serem assintomáticas, em alguns casos poderão evoluir para várias doenças gástricas como 
gastrite crónica, úlceras pépticas, carcinoma gástrico e linfoma MALT. A vacinação contra infecções 
por H. pylori poderá ser uma alternativa promissora, devido aos problemas emergentes dos 
tratamentos à base de antibióticos. Pensa-se que a vacinação oral poderá ser uma boa abordagem para 
uma imunidade protetora mais eficaz contra infecções por H. pylori, criando uma primeira linha de 
defesa ao nível das mucosas. Nanoparticulas de quitosano têm mostrado ser um vínculo adequado para 
vacinação por via oral, devido às suas propriedades imunogénicas e mucoadesivas, conferindo 
proteção do DNA, e permitindo níveis elevados de células transfectadas. Este trabalho visa avaliar 
uma vacina baseada em DNA plasmídeo e proteína recombinante, constituída por múltiplos epítopos 
de diferentes antigénios de H. pylori.  
Após produção e purificação do pDNA e da proteína recombinante, foram formuladas vacinas 
para administração oral e intramuscular com os antigénios encapsulados em nanoparticulas de 
quitosano. O tipo de resposta imunitária gerada e a eficácia da imunidade protetora foi avaliada por 
ELISA, através da análise dos níveis de IgGs especificos, de SIgA e de citoquinas produzidas, 
presentes nos soros de ratos BALB/c imunizados. Quando administradas pela via intramuscular, as 
vacinas formulada com pDNA e proteína recombinante estimularam eficientemente a produção tanto 
de IgG1 como de IgG2a, resposta suportada pelos níveis de citocinas produzidas, revelando uma 
resposta imunitária sistémica mais consistente e equilibrada do que imunizações por via oral. No 
entanto, como esperado, imunizações por via oral revelaram níveis elevados de SIgA, mostrando-se 
eficaz na imunização da mucosa gástrica conferindo uma maior imunidade protectora, em contraste 
com imunizações por via intramusculares que não induziram secreção de IgAs. 
Os resultados obtidos das imunizações mostraram que ambas as vacinas formuladas com pDNA e 
proteína recombinante são boas candidatas para o desenvolvimento de uma vacina futura para uso 
profilático e terapêutico de modo a erradicar infecções por H. pylori. 
 
 
Palavras-chave: Helicobacter pylori; vacina; vacina de DNA; imunização; antigénios 
recombinantes. 
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1.1. Historical perspective 
 
Since the early of 20th century several investigators have reported the presence of spiral 
microorganisms in the stomach of several animals (Kusters et al., 2006; Dubois, 2007). In 1906, 
Walter Krienitz was the first to report the observation of spiral bacteria in the human stomach, 
suggesting that spiral-shaped bacteria were causing gastric diseases, but it was not possible to make a 
consistent association between the presence of this bacteria and any specific disease. In 1983, 
Helicobacter pylori were successful isolated and cultured for the first time by Warren and Marshall. 
Self-ingestion experiments by Marshall demonstrated that these spiral bacteria can colonize the 
healthy human stomach and inducing inflammatory response in the gastric mucosa, developing a 
transient gastritis, as proved by gastric biopsy samples taken from B.J. Marshall (Marshall et al., 
1985). This discovery was worth the 2005 Nobel Prize in physiology or medicine to Robin Warren 
and Barry Marshall for their “Discovery of the bacterium Helicobacter pylori and its role in gastritis 
and peptic ulcer disease.” (Kusters et al., 2006). This knowledge showed that gastric colonization with 
H. pylori can lead a variety of gastrointestinal disorders, such as chronic gastritis, duodenal ulcers 
(DU) or gastric ulcers (GU), gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and 
gastric cancer (GC). This discovery prompted efforts by other scientists in the study of the physiology, 
genetics, transmission and epidemiology of this bacterium (Kusters et al., 2006). The result was an 
increasing number of scientific manuscripts up to about 30 thousand manuscripts published in the past 
20 years. 
 
 
1.2. Helicobacter pylori  
 
H. pylori is a gram-negative bacterium, spiral-shaped, microaerophilic, with 3 to 7 unipolar 
flagels, that allow the bacteria to move along the mucus layer to gastric epithelium and colonize the 
antral region (the most distal region) of the human stomach after oral ingestion (Amieva and El-Omar, 
2008). 
Most H. pylori organisms are free living in the mucus layer, but some organisms attach to the 
apical surface of gastric epithelial cells and after attachment always elicit an acute inflammatory 
response (gastritis) in the stomach mucosa (Velin and Michetti, 2010). 
The stomach has a too acid and hostile environment unfavorable to the presence of most 
microorganisms, due to large amounts of gastric juice composed by digestive enzymes and 
hydrochloric acid (Amieva and El-Omar, 2008; Zhou et al., 2009). H. pylori has a unique mechanism 
that allows it to survive a transient exposure to this acid environment of the stomach for a few 
minutes, by secreting a large amount of the enzyme urease that hydrolyses urea into ammonia and 
carbon dioxide, partially neutralizing the acidic pH of the stomach lumen (Kabir, 2007). Indeed, all 
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known gastric Helicobacter species are urease positive but also highly mobile through flagella. This 
motility permits rapid movement toward the more neutral pH of the gastric mucosa. Both factors are 
prerequisites for colonization of the human stomach and will allow trigger an inflammatory response 
in epithelial cells (Figure 1.2.1) (Kusters et al., 2006). The enzyme urease along with lipases, 
proteases and others virulence factors produced by the bacterium will disrupt the defenses of the 
mucus layer and will lead to the success of infection.  
 
 
Figure 1.2.1 – H. pylori infection: Colonization and infection of the most distal part of the stomach, 
the antrum. Adhesion, urease and other virulence factors are important to H. pylori surviving in a 
transient exposure to low pH environments: to avoid the acid lumen of the stomach for long 
exposures, H. pylori swims toward the mucosal cell surface using their polar flagella and chemotaxis 
mechanisms. As near the epithelium, H. pylori actively adheres to the cell surface using a variety of 
specific adhesions that recognize glycoproteins on the host cell. Attachment to the host cells allows H. 
pylori to deliver toxins like VacA and CagA that deregulate some of host cell functions. This 
mechanisms lead to a consequent inflammatory response causing gastritis. Adapted from “Press 
Release: The 2005 Nobel Prize in Physiology or Medicine” and Amieva and El-Omar (2008).  
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1.2.1. Virulence factors 
 
H. pylori has a high genetic variability among strains, due to a high rate of mutation and 
recombination, horizontal transfer of DNA and the lack of mismatch repair system of DNA. This leads 
to a high diversity of genes and a high number of alleles, essential for adaptation and colonization of 
the hostile environment of the stomach (Suerbaum and Michetti, 2002). Bacterial virulence factors 
play an important role, since the virulent strains are more aggressive and increase the risk of 
developing severe clinical manifestations. These virulence factors also play structural and critical roles 
and functions such as adhesion, invasion, colonization and virulence. Some antigens have been 
extensively studied and tested, known to be involved in the pathogenesis of the infection and shown to 
be safe and promising, due to its pathogenic importance, immunogenicity and representativeness in a 
large number of strains. These antigens include urease, the Neuraminil-lactose hemagglutinin 
connection (HpaA), the vacuolating cytotoxin (VacA), the cytotoxin-associated antigen (CagA), the 
neutrophil-activating protein (NAP) and others (Del Giudice et al., 2009; Velin and Michetti, 2010). 
Urease is an enzyme that catalyzes urea into ammonia (NH3) and carbonic acid (H2CO3), which 
in turn is converted into CO2 and H2O, and is crucial for the survival of the H. pylori in the human 
stomach. This enzyme is present in all strains and because of that its activity is used for detected H. 
pylori infections as in urea breath test (UBT) (discussed in section 1.7.) and gastric biopsy samples 
(urease test). It is composed by 12 urease alpha (UreA) and 12 urease beta (UreB) subunits with 
molecular mass of approximately 27 kDa and 60 kDa each, respectively, being the UreB subunit most 
commonly used for immunization (Begue and Sadowska-Krowicka, 2010; Calvet et al., 2010). 
The virulence factor HpaA or adhesion A is a protein that works as an adhesion present in 
flagellar filament of flagella and on the bacterial surface, essential to colonization and infection. 
Studies with hpaA mutants showed this protein is necessary for motility and for establishment of a 
stable colonization. HpaA is highly immunogenic and leads to induction, maturation and antigen 
presentation by dendritic cells (Lundstrom et al., 2001; Voland et al., 2003; Carlsohn et al., 2006). 
HomB is a Helicobacter outer membrane protein (OMP) that permits the attachment of the 
bacteria to the gastric epithelium to avoid the bacteria elimination by peristaltic movements. Bacterial 
adherence to ephitelial cells leads to an induce of inflammatory response through activation of IL-8, 
leading to PUD. This makes this protein a co-marker for strains associated with peptic ulcers, as well 
as with the presence of other H. pylori disease-related genes like cagA, babA and vacA. (Oleastro et 
al., 2008). 
Vacuolization cytotoxin VacA, is an exotoxin that is involved in various mechanisms of virulence 
such as induction of cytoplasm vacuolization in epithelial cells that can cause disruption of the 
epithelial barrier due to formation of pores, membrane channels and cellular damage,  targeted to the 
mitochondrial membrane where it causes release of cytochrome c and induces apoptosis (showed at 
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Figure 1.2.1.1) and phagocytosis inhibition by macrophages (Suerbaum and Michetti, 2002; Wilson 
and Crabtree, 2007). 
 
 
Figure 1.2.1.1 - Mechanisms of action of VacA on host gastric epithelial cells and its effect on 
immune cells. Surface bound VacA may function as an adhesion (1), while secreted VacA may bind to 
a host receptor and induce pro-inflammatory response (2) or induce apoptosis mediated by cytochrome 
c (in green) release (3), or induce vacuolation by alterations in endocytic vesicles (4), or form a 
membrane channel leading in exit of nutrients and ions to the extracellular space (5), or achieve the 
lamina propria where it binds to immune cells causing immune system modulation (6). Adapted from 
Cover and Blanke (2005) and Jones et al. (2010). 
 
 
The VacA gene is present in all known H. pylori strains but the activity of the protein depends on 
this polymorphism of two regions of the gene, s-region (s) and mid-region (m). Each s and m regions 
present two polymorphisms, s1 and s2, and m1 and m2. Strains having s1/m1 vacA gene have the 
highest vacuolization activity, when s1/m2 strains present VacA activity but has a restricted number of 
affected cells, and activity of the protein is absent in presence of s2/m2 strains. The S2/m1 genotype is 
very rare (Letley and Atherton, 2000; McClain et al., 2001). VacA vacuolization activity is codified 
by s-region while the toxin binding to epithelial cells is related to m-region. A third variable region, 
located between the s- and m-region, was identified as intermediate (i) region, and i1 is associated to 
the vacuolization form and i2 is associated to the non-vacuolization form. Was observed that while all 
s1/m1 strains were of type i1 and s2/m2 were type i2, s1/m2 could be both i1 and i2, varying in their 
toxicity (Rhead et al., 2007). 
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VacA gene was identified as mostly common and encodes a highly antigenic protein due to 
induce the production of pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-8 in immune cells, 
and showed to have an immunosuppressive effect on them. It will inhibit T cell activation interfering 
with calcium-signaling events inside the cell and prevented activation of the calcium-dependent 
phosphatase calcineurin, inhibit the proliferation of T and B lymphocytes and will interfere with 
phagocytosis and antigen presentation (Backert et al., 2010). 
The cag-pathogenicity island (cag-PAI), a 40kb DNA segment of the H. pylori genome, encodes 
both CagA protein and type IV secretion system (T4SS). This system translocates the CagA protein 
into the epithelial cells through a pilus responsible for the delivery of bacterial proteins such as CagA, 
inside the host cells, during infection (Covacci et al., 1993; Censini et al., 1996; Vitoriano et al., 
2011). The entry of CagA, will lead to increased inflammation and to activation of adaptative 
immunity, disruption of tight junctions, cytoskeleton rearrangements, oxidative stress that leads to 
apoptosis and DNA damage, and induce secretion of IL-8 cytokine activating Dendritic Cells and IL-
12 cytokine, that will stimulate Th1 cells too (Vitoriano et al., 2011). CagA protein is one of the most 
important and well-characterized virulence factors of H. pylori. For that reason it is essential for 
stimulating the immunity to protect the host against H. pylori infections.  
When injected in the host cell, CagA is phosphorylated and interacts with several epithelial cells 
effectors proteins of the host. Additional bacterial factors are injected through the T4SS, such as 
peptidoglycan, that also interact with host proteins. These interactions with host protein effectors by 
cag-PAI genes products, results in the deregulation of signalling pathways associated with host cell 
motility and elongation, proliferation, inflammatory response, disruption of cell junctions and 
phagocytosis inhibition. It was demonstrated that cag-PAI positive strains induces the development of 
gastritis and GU, when compared to mutants for cag-PAI-encoding proteins (Tegtmeyer et al., 2011). 
 
 
1.3. Epidemiology of Helicobacter pylori infection 
 
It is estimated that more than a half of global population is infected with H. pylori and its 
prevalence differs according to geographic location. Within the same country, the prevalence of H. 
pylori is influenced by patients’ socioeconomic status, age, gender and genetic predisposition. Among 
countries, the prevalence is higher in developing countries were achieves 80-90%, when compared to 
developed countries with 10-60% of prevalence (Figure 1.3.1) (Del Giudice et al., 2009; Khalifa et al., 
2010). The prevalence of infection is especially higher in the rural developing areas in contrast to 
urban developed ones because in rural environments people are probably exposed to an increased 
number of infectious sources such as contaminated food and water, or intensive contact between 
infants and non-parental caretakers and poor sanitation and hygiene cares (Vale and Vitor, 2010). 
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The route of transmission of H. pylori is not completely understood but is thought that new 
infections occur as a consequence of direct human-to-human transmission or by environmental 
contamination. There are evidences that infection by H. pylori can occur by gastro-oral, oral-oral and 
fecal-oral routes, but these data are inconclusive (Vale and Vitor, 2010). 
Infection occurs typically in early childhood, frequently transmitted within families through 
mother-to-child transmission, but the role of these vehicles in H. pylori transmission remains to be 
clarified (Kabir, 2007). Unless treated, colonization usually persists during lifelong (Kusters et al., 
2006). 
 
 
Figure 1.3.1 - Prevalence of H. pylori infection around the world in asymptomatic adults (Crew and 
Neugut, 2006). 
 
Most infections remain asymptomatic, however, in some cases and if not treated the infected may 
develop for a chronic gastritis, gastro-duodenal ulcer, gastric adenocarcinoma or mucosa-associated 
lymphoid tissue lymphoma, depend on the inherent properties of the bacterial strain, virulence factors, 
genetic predisposition and the immunological response of the host.  Gastric cancer is the fourth most 
common cancer and the second most common cause of cancer death in the world (Jemal et al., 2011). 
Since 1994 the World Health Organization classifies the bacterium as a type I carcinogen (Kabir, 
2007; Lima and Rabenhorst, 2009). 
 
 
1.4. Helicobacter pylori Infection and Immune system 
 
The innate immune system represents the first line of defence against pathogens and provides an 
unspecific response. After colonization by H. pylori, the pattern recognition receptors (PRR), like 
Toll-Like Receptors (TLRs), are the first involved in the recognition of conserved microbial 
constituents called pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides 
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(LPS), peptidoglycan (PG), flagellins, RNA and DNA molecules. TLRs are expressed by epithelial 
cells, including gastric epithelial cells and by specialized antigen presenting cells (APCs) such as 
macrophages and dendritic cells (DC). Activation of TLRs triggers several signaling pathways, 
including activation of cytokines production, stimulate the migration of neutrophils, and induce the 
activation of macrophages and maturation of DCs in the gastric mucosa, leading to an inflammatory 
response (Kindt et al., 2006). 
APCs will trigger and stimulate the adaptive immune response through the ability to capture, 
process and present antigens to other cells, presenting the peptides fragments of antigens connected to 
surface molecules of Major Histocompatibility Complex (MHC) class I and II. Intracellular antigens 
(like viral proteins) are presenting by molecules of MHC I which activate T CD8+ lymphocytes 
(CTLs) and extracellular antigens are endocyted and presenting to molecules of MHC II which 
activate T helper (Th) CD4+ lymphocytes (Kindt et al., 2006). 
Macrophages are one of those APCs and are also involved in the amplification of the 
inflammatory immune response producing more cytokines, such as IL-1, TNF-α and IL-6, and along 
with DCs are activators of adaptive immunity producing cytokines such as IL-12, that stimulate 
differentiation of Th lymphocytes (Kawai and Akira, 2011). Other APCs involved in activation of 
adaptive immunity are DCs. These cells, after capture and process antigens, which are transported 
linked to molecules of MHC class I and II, migrate to secondary lymphoid organs, leading to 
activation of T lymphocytes and differentiation of B lymphocytes thereby initiating a specific immune 
response against the antigens of the pathogen (Wilson and Crabtree, 2007). 
The adaptive immune system is the second line of defence and is able to provide highly specific 
responses against pathogens. After presentation of antigens to the specific surface receptors linked to 
MHC class II, both humoral and cellular immune responses in the infected host are triggered.  
T lymphocytes are divided into two lineages: T helper (Th) lymphocytes that express CD4 +, 
stimulated by MHC II, and cytotoxic T lymphocytes (CTL) expressing CD8+ to the surface, 
stimulated by MHC I (Kindt et al., 2006). 
The cytokines produced by APCs such as IL-12, will stimulate activation and recruitment of 
lymphocytes and the development of T helper (Th) response. Two types of T CD4+ lymphocytes will 
be stimulated: Th1 lymphocytes and Th2 lymphocytes. Th1 cells are induced in the presence of 
intracellular pathogens and mediate the cellular immune response through the production of a set of 
cytokines that include interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2. These 
cytokines will activate the CTLs and enhance phagocytosis. Thus CTLs will eliminate the infected 
cells by a mechanism mediated by antibodies. In the other hand, Th2 are stimulated in the presence of 
extracellular pathogens, mediating the humoral immune response, characterized by production of 
cytokines such as IL-4, IL-5, IL-6, IL-10 and IL-13 (Wilson and Crabtree, 2007). 
After activation, Th cells will stimulate B lymphocytes to produce immunoglobulins. Associated 
to Th1 response are induced IgG2a (and IgA) and to Th2 response are expressed IgG1.  
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The CD4
+ T cells activated by antigens linked to MHC II molecules are crucial to protection 
against H. pylori infections. It is known that H. pylori induces a polarized Th1 response and being a 
non invasive microorganism was expected that induce a mediate Th2 response, but this is not observed 
(Suerbaum and Michetti, 2002). Studies have shown that H. pylori-infected patients have an increased 
of IFN-γ producing T-cells, consistent with Th1 cytokine response and mucosal T-cells produce high 
levels of Th1 cytokines such as IFN-γ and IL-2, unlike Th2 cytokines such as IL-4 and IL-5 that has 
not been detected in the gastric mucosa of infected individuals (Peek et al., 2010; Velin and Michetti, 
2010). The persistent H. pylori infections typically result in Th1-polarized responses, whereas 
successful H. pylori immunization could result in Th1/Th2 balanced response (Algood and Cover, 
2006). It could then be concluded that the immune system is unable to clear off H. pylori infection. 
Studies have shown that H.pylori is capable of compromise the host immune response through 
virulence factors that interfere with T-cell proliferation (Velin and Michetti, 2010). 
Thus, the immune response production in presence of H. pylori is inefficient to eliminate the 
infection and will contribute to the tissue damage like apoptosis and DNA damage, duo to the 
inefficient immune response by Th2 cells which leads to continuous neutrophil and macrophag 
activation, consequent inflammation persistence and constant production of cytokines such as IFN-γ 
(Wilson and Crabtree, 2007). 
 
 
1.4.1.  Mucosal immunity 
 
M cells are the major effector cells in the mucosal lymphoid tissues, taking up the antigens or 
microorganisms by phago-, endo-, or pinocytosis and delivery to the APCs. The mucosal lymphoid 
tissues can be divided into effectors sites and inductor sites. Antigens are presented the inductor sites 
leading to an activation of immune system cells. The effector sites are the locals where the antibodies 
and the immune cells act. The main sites of induction of mucosal immune system are the MALT 
components, which include the gut associated lymphoid tissue (GALT), the bronchus-associated 
lymphoid tissue (BALT), the nasopharynx associated lymphoid tissue (NALT) and the genital 
mucosa-associated lymphoid tissue (GENALT). At the MALT, some PPRs interact with PAMPs of 
the microorganisms for the translocation the bacteria across the epithelial barrer (Azizi et al., 2010). 
The main effector cells at mucosal surfaces are constituted by CD8+ and CD4+ T. The APCs like 
macrophages, DCs and B lymphocytes process and present antigens to activate CD4+ T cells and CD8+ 
T cells. Therefore, the proximity of APCs to the T and B lymphocytes at the induction sites of mucosa 
are essential for the success of an efficient immune response (Wilson-Welder et al., 2009). 
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1.5. Helicobacter pylori associated diseases 
 
H. pylori is therefore considered the main etiologic factor in chronic gastritis, PUD (peptide ulcer 
disease) and GC. The infection, despite being asymptomatic in most individuals, can evolve and cause 
different gastric disorders, such as those shown in Figure 1.5.1. In most of symptomatic infected 
individuals the colonization by H. pylori can cause acute gastritis which if not treated will progress to 
a chronic gastritis that will affect both antrum and corpus. In 10-15% of infected patients, chronic 
gastritis occurs only in gastric antrum and these cases will result in DU outcomes, characterized by 
excessive acid and gastrin secretion in antral zone of the stomach. Another gastric phenotype is 
characterized by gastritis in corpus zone of the stomach, which occurs in 2-5% of the infected 
individuals that leads to GU with hypochlorhydria and acid reduction and may evolve into GC  
(Amieva and El-Omar, 2008; Schubert and Peura, 2008; Konturek et al., 2009). 
 
 
Figure 1.5.1 – Chronic H. pylori infection: Chronic H. pylori infection can lead to different gastric 
diseases such as chronic gastritis, duodenal ulcer and gastric cancer. Adapted from Amieva and El-
Omar (2008). 
 
 
1.6. Diagnosis and Treatment  
 
Infection with H. pylori can be diagnosed by both non-invasive and invasive methods. Invasive 
tests are based on endoscopic biopsy of the gastric mucosa, collecting samples for diagnosis of 
gastritis, ulcerogenic lesions, gastric atrophy, intestinal metaplasia and GC lesions. To confirm the 
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presence of H. pylori tests are performed such as urease test, bacterial culture and histological analysis 
of the biopsy samples. In addition, H. pylori can also be detected using molecular methods, such as 
PCR and real-time PCR applied to specific H. pylori genes (Suerbaum and Michetti, 2002). 
Non-invasive tests include the urea breath test (UBT), serologic tests, search of stool antigens and 
urine tests. The commonly used is the urea breath test (UBT) and is based on the abundant H. pylori-
derived urease activity in the stomach (detection of 13CO2 and 
14CO2). For routine diagnostic the most 
used test is UBT with an accuracy of >90%, while for large number of samples, such as 
epidemiological studies, faecal antigen test is most appropriate, although less accurate (Suerbaum and 
Michetti, 2002). 
Current triple therapies for H. pylori eradication include two antibiotics in combination with a 
proton pump inhibitor (PPI). Commonly used antibiotics for H. pylori eradication therapy include 
macrolides (usually clarithromycin), tetracycline, amoxicillin and imidazoles (predominantly 
metronidazole) as the first-line therapies. Antimicrobial resistance is the primary cause of treatment 
failure, but antibiotic treatment has others emerging problems such as antibiotic side effects, re-
infections, and recurrence and has high-costs (Zhou et al., 2009). 
For these reasons is essential to develop new therapies and other therapeutics approaches such as 
an effective preventive and therapeutic vaccine against H. pylori, that stimulates an effective humoral 
response as well as cellular response, capable of prevent and effectively eliminate the infection. 
 
 
1.7. Vaccines 
 
Thought to be therapeutic vaccination the solution for clearance and eradicate infection by H. 
pylori, efforts are being made in toward to develop a vaccine that has a prophylactic use to prevent 
infection and a therapeutic use to eradicate an ongoing infection (Kabir, 2007). Vaccination presents a 
major benefit/cost ration and has major advantages such as financial, while avoiding re-infections and 
decrease antimicrobial resistances. 
Some prophylactic and therapeutic vaccine strategies using a wide variety of H. pylori antigens 
have been reported (Del Giudice et al., 2009) and will be referred to in the following sections. 
 
 
1.7.1.  Types of vaccines 
 
Several clinical studies have been made in order to develop an efficient vaccine capable of induce 
a protective immune response for eradicate ongoing infections and in order to test the 
immunogenicity, safety and efficacy of potential H. pylori vaccines.  
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Vaccines with attenuate H. pylori are extendedly study, due to have the advantage to having all 
the H. pylori antigens, but these vaccines can lead to safety problems due to mutations that lead a 
reversion on virulence or to an insufficient attenuation, which may ultimately induce the infection 
(1.7.1.1.2). Alternatively there are inactivated whole killed vaccines that such as attenuated vaccines 
have the advantage of containing all bacteria antigens, but without the danger of virulence reverting. 
Studies with H. pylori inactivated whole-cells combined with LT adjuvant showed a significant rise in 
specific IgA antibodies, but did not show success in eradicating the pre-existing infection (Wilson and 
Crabtree, 2007). Despite inactivated whole-cell vaccines have the advantage of elicit immune response 
against all antigens known and unknown of the bacteria, this can be also a disadvantage since it 
contains other dangerous components of the bacterium that could induce a cross-reacted immunity 
responses (Kabir, 2007; Wilson and Crabtree, 2007; Ingolotti et al., 2010). 
The protection induced by several H. pylori antigens was described, including recombinant 
antigens and strain-specific virulence factors of the bacterium. In addition to urease, protection with 
CagA, VacA, NAP and GroEL has been demonstrated (Wilson and Crabtree, 2007), but it has been 
concluded that given the genomic variability and variation of H. pylori antigens, an optimal vaccine 
must be contain multiple antigens. As an example, recombinant H. pylori urease with E. coli LT (E. 
coli heat-labile toxin) orally administrated to H. pylori infected volunteers, demonstrated the 
immunogenicity of the vaccine through the observation of a reduction in bacterial load in vaccinated 
individuals compared with controls, but the eradication of the infection was not accomplished and the 
degree of gastritis remained unchanged (Kabir, 2007). 
Other approach for immunization against H. pylori has been delivering antigens in live vectors 
such as attenuated Salmonella typhimurium and modified poliovirus. Salmonella-based recombinant 
vaccine expressing urease was orally administrated but most of the volunteers presented specific IgG 
to the Salmonella vector and none of them showed any detectable mucosal or humoral immune 
response against urease. Vaccines vectors using poliovirus genomes (replicons) also have been 
described as a protective way to immunized mice: capsid genes were replaced with urease B subunit 
and administered by systemic route and showed both prophylactic and therapeutic efficacy against H. 
pylori, clearing an established infection in mice (Wilson and Crabtree, 2007).  
Although these types of vaccines have proven their efficacy in inducing some type of immune 
response, they do not retain the security requisites needed and the strong humoral immune response 
induced alone do not provide protective immunity against subsequent contacts with the pathogen 
(Shedlock and Weiner, 2000). 
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1.7.1.1.  DNA based vaccines 
 
On other hand, there are the DNA vaccines, whereby naked plasmid DNA, introduced into the 
host, is taken up by eukaryotic host cells and the encoded antigen is expressed (Figure 1.7.1.1.1). The 
gene sequence of the antigens of interest is inserted in a bacterial plasmid backbone. The 
transcriptional unit containing the nucleotide sequence should be under the control of an eukaryotic 
housekeeping gene promoter and should be followed by a polyadenylation sequence (poly[A]) to 
ensure the stability of the mRNA molecule and its translation. One of the most commonly used is the 
cytomegalovirus (CMV) promoter. The plasmid backbone should also contain an origin of replication 
for amplification the plasmid in bacteria and an antibiotic resistance gene to enable the selective 
growth of transformed bacteria. Thereby, there is a commercially available plasmid approved by the 
Food and Drug Administration, “pVAX1” (Invitrogen) specially designed for DNA vaccines (Ingolotti 
et al., 2010). 
 
 
 
Figure 1.7.1.1.1 – Plasmid DNA backbone scheme 
for DNA vaccines with gene sequence of interest, 
polyA sequence, promoter and origin of replication, 
and antibiotic resistance gene for selection of 
competent bacteria (Ingolotti et al., 2010). 
 
 
 
The advantage of DNA vaccines, compared to protein-based vaccines (figure 1.7.1.1.2), is the 
possibility to triggering both humoral and cellular immune response, so that the infected host can 
quickly and effectively respond to the infection and efficiently eliminate the pathogen. DNA vaccines 
stimulate the antigen presentation both by MHC I to the CD8+ T cells (TCL) and by MHC II to the 
CD4+ T (Th) (Wilson and Crabtree, 2007). 
In a simplistic view of the DNA vaccine mechanism, the DNA plasmid upon transfection is 
translocated to the cell nucleus and uses the host cell machinery to transcribe and translate the genes. 
The resulting proteins are recognized by the host cells as non-self and undergo cleavage resulting in 
fragments that will be presented on the cell surface by MHC I. Moreover, the antigenic protein 
secreted by the transfected host cells can be taken by APCs, which present it on the cell surface MHC 
II. Also, apoptotic transfected cells can be engulfed by APCs which will present the antigen through 
MHC I and MHC II. This will stimulate the both naïve CD8+ T cells and CD4+ Th cells. Activated 
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CD4+ Th cells and a cascade of cytokines will activate B cells which induce antibody production. The 
CD8+ T cells will lyse transfected cells which presenting antigens through MHC I causing the release 
of more antigens and CD4+ Th cells activated by DCs, which will repeat this cycle of activation. So 
both T and B cells migrate to the site of immunization and are re-stimulated (Kutzler and Weiner, 
2008; Ingolotti et al., 2010). 
To improve the efficacy of DNA vaccines could be encoded only some epitopes, instead the 
whole antigen in order to avoid potential dangerous components of the bacterium such as those 
sharing homologies with self-antigens and thus avoid cross-reactive immune responses against host 
epitopes. These vaccines have the advantage of including only the potential epitopes selected, 
considering only the PAMP highly conserved among strains. (Del Giudice et al., 2009; Zhou et al., 
2009; Moss et al., 2011). 
Studies suggest that a DNA-prime and peptide-boost vaccine designed with multiple H. pylori 
epitopes has a therapeutic efficacy in mice previously infected with H. pylori. Has showed that the 
multi-epitope vaccine induced a broad immune response that lead to a significant reduction of H. 
pylori colonization. So these studies suggest that further development of an epitope-based mucosal 
vaccine against H. pylori can potentially lead to a novel approach to prevent H. pylori associated 
diseases (Moss et al., 2011). 
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Figure 1.7.1.1.2 – Resume of the Mechanisms of action of different types of vaccination: 
attenuated vaccines, inactivated vaccines, subunits vaccines, toxoids vaccines and DNA vaccines; 
Advantages and disadvantages (Ingolotti et al., 2010).  
 
A variety of factors could affect the frequency of integration of plasmid DNA vaccines into host 
cells, including DNA sequences within the plasmid, the expressed gene product (antigen), the 
formulation, delivery system and route of administration. A proper route of administration and a 
suitable delivery system could provide a better and highly immune response against infections H. 
pylori. So, in this and others studies in our research group, effords were made for chose a proper route 
of administration and develop an appropriated delivery system for enhance the potential of immune 
protection induced by our vaccines.  
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1.7.2.  Routes of vaccination  
 
Most vaccines are administered through parenteral administration, such as intramuscular or 
subcutaneous. However, mucosal vaccination presents several advantages since most pathogens infect 
their host through mucosal membranes, as the respiratory tract, gastrointestinal, vaginal and urinary 
tract, suggesting mucosal vaccination is essential to create a first line of immunization at mucosal 
level. Thus, mucosal vaccines have the benefit of not only stimulate the mucosal immunity as well as 
trigger systemic immune response, resulting in a stronger protective immunity. Other advantages 
include non-invasiveness, which improve patient compliance, avoiding the use of needles, ease self-
administration, low costs and ease production and application, and low risks of needle infections 
(Vajdy et al., 2004; Sijun and Yong, 2009; Azizi et al., 2010; Chadwick et al., 2010; Cadete et al., 
2012). 
Recent studies indicate that oral route is the ideal mucosal route for induction predominantly 
secretory IgA antibody in gastric mucosa to confer  effective for protection against H. pylori 
infections, preventing direct contact of the bacteria with epithelial cells (Strugnell and Wijburg, 2010; 
Velin and Michetti, 2010).  
Some studies have been made but with reduced success (Moss et al., 2011), since mucosal 
inoculation require a successful delivery system for the vaccines efficiency, which constitutes a 
challenge because mucosal membranes are constituted mainly of epithelial tissue highly vulnerable 
with viscous mucus secretion that acts as a barrier against pathogens and against vaccine antigens. 
These disadvantages may decrease the lifetime of antigens and difficult the determination the amount 
that effectively penetrates the mucosa (Neutra and Kozlowski, 2006). 
Thus, these vaccines have to be capable of effectively penetrate the mucus epithelial cells without 
any damage, penetrate through the epithelium and interact with APCs or directly with MALT. For the 
success of mucosal DNA-based vaccines it is essential to use suitable vaccine formulations working 
both as adjuvants and delivery systems (Del Giudice et al., 2009).   
It is known that vaccination through mucosal membranes requires potent adjuvants or delivery 
systems to enhance the immunogenicity of the antigens as well as to protect the antigens form 
degradation and to prolong the contact with the epithelium. 
   
 
1.7.3.  Adjuvants and Delivery systems 
 
Adjuvants are molecules, compounds or macromulecules that do not have any specific effect of 
antigen but can be co-administered with pathogen-derived antigens improving the efficacy of vaccines 
with less reactive antigens and enhance a longer and stronger specific immune response, without 
causing immune reaction against themselves. They are essential to confer enhanced antigen 
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immunogenicity, through a proper transport and delivery system for presenting antigens to specific 
cells of the immune system and to confer ability to prolong drug release. On the other hand, have to be 
cost-effective, easily produced and present high stability (Vajdy et al., 2004). 
Adjuvants can be divided into antigen-binding systems such as emulsions, micro and 
nanoparticles, immunostimulatory complexes (ISCOMs) and liposomes, and immunostimulatory 
adjuvants such as lipopolysaccharides (LPS), monophosphoryl lipid A, etc (Shahiwala et al., 2007). 
The chemical composition of each vaccine is critical to defining the type of immune response that 
will develop, stimulating a specific type of antibodies of interest secreted by B cells, and stimulating 
specific cytokines secreted by T cells. This cascade of events can be controlled through the 
combination of antigens associated with adjuvants (Vajdy et al., 2004; Shahiwala et al., 2007). 
It is well known that some antigens in their soluble form are not recognised by APCs and 
therefore do not induce a protective immune response. The therapeutic use of particulate carriers for 
the development of protective immune responses is currently one of the most promising strategies to 
fight infectious diseases (Shedlock and Weiner, 2000; Florindo et al., 2009). 
There are a few adjuvants approved for human use. These usually raise issues of potential 
toxicity, intolerable reactogenicity and side effects. A number of experiments with H. pylori vaccines 
with different adjuvants, such as E.coli heat labile enterotoxin (LT), mutant LT, cholera toxin (CT), 
typhoid vaccine Ty21a and aluminum hydroxide have been described, but none of these adjuvants 
showed protective immunity and some were unable to eliminate ongoing infection (Kabir, 2007). 
Aluminum hydroxide is the widely used adjuvant, with reduced side effects but has the disadvantage 
of triggering an unbalanced response essentially the prevalence of Th2 type with humoral component, 
having reduced stimulation of the cellular component. Other approach to delivering H. pylori vaccines 
is the use of attenuated Salmonella typhimurium and modified poliovirus, but none of them succeeded 
in eradication of H. pylori without triggering a successfully immune response in the host (Kabir, 2007; 
Velin and Michetti, 2010; Moss et al., 2011). 
Accordingly, therapeutic use of particulate carries for the development of protective immune 
responses is currently one of the most promising strategies against infectious diseases. It is believed 
that particulate systems for delivery the antigens could be the most advantageous because they confer 
antigen protection against mucosal enzymes, promote the sustained release of antigens increasing the 
time of contact between antigens and APCs, and possibility of increased time of retention in the 
administration site through adhesion. Since particulate systems have dimensions similar to pathogens, 
they are easily recognized and phagocytosed by APCs (Florindo et al., 2010). 
Chitosan nanoparticles are thought to be a suitable vehicle for oral DNA vaccine delivery because 
it is one of the most promising polymers for drug delivery through mucosal routes. Chitosan is 
biocompatible and biodegradable, as well as mucoadhesive and permeation-enhancing. Its 
mucoadhesive characteristics allow prolonged exposures of the antigens with the mucosal epithelium. 
It has been extensively used in drug and vaccine formulations to be administered by mucosal routes. 
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Studies reported no effects on cell viability, high levels of gene expression in the epithelial cells of 
both stomach and intestine. Nanoparticles made of chitosan, showed stability under physiological 
conditions of the intestine and also for short periods of time in the stomach. For these reasons chitosan 
particles are good candidates for the development of novel gastrointestinal drug and DNA delivery 
systems. Nanoencapsulation of DNA into chitosan nanoparticles showed efficient nanoparticles 
binding to cellular membranes leading to transfection and effective immune system stimulation 
triggering both humoral and cellular responses (Boyoglu et al., 2009). Other studies show that 
intranasal administration with tetanus toxoid-loaded chitosan nanoparicles increases humoral response 
as compared to the soluble antigens. 
 
 
1.8. Aims 
 
The ultimate aim of this research project, where the work of this thesis is included, is to develop a 
prophylactic and therapeutic efficient multigenic DNA-based vaccine against H. pylori. In this 
direction, this work aims to evaluate a pDNA- and recombinant protein-based vaccine encoding multi 
epitopes from different H. pylori antigens capable to induce an effective humoral as well as cellular 
immune response against H. pylori infections and capable of eradicating the pathogen. For that 
propose, a plasmid DNA was produced, encoding the specific epitopes of selected antigens, and 
expressed in an appropriated expression vector. To evaluate the immune response triggered after 
vaccination, the recombinant proteins and plasmid DNA were purified and encapsulated in a specific 
nanoparticulate delivery system and the immune response was assessed by ELISA. The results could 
contribute to the positive development of an efficient prophylactic vaccine against H. pylori infections. 
Positive results will lead to a new approach in the development of novel vaccines for other infectious 
diseases. 
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2.1. Antigen production  
 
2.1.1. Cell transformations  
 
Escherichia coli XL1-Blue cells (Stratagene,USA) (200 μL), made competent by CaCl2 
treatment, were transformed by heat shock method with two plasmids vectors pQE30 (6T) (Qiagen, 
Germany) and pVAX1 (6T-plamid) (Invitrogen, UK), containing the recombinant gene for the 
following fragment antigens of H. pylori CagA, UreB, HpaA, VacA, GroEL, Homb (Figure 2.1.1.1). 
The positive clones were selected in agar with ampicillin for clone 6T and kanamycin for 6T-
plasmid. The cells were expanded and a cell bank was produced and preserved with 20% glycerol at    
-80ºC. Each production either of protein or plasmid was obtained from the same cell bank. 
 
 
Figure 2.1.1.1 - H. pylori DNA and protein vaccines. Schematic representation (not to scale) of the H. 
pylori vaccine construction. 
 
 
 
 
2. Materials and Methods 
24 
 
2.1.2.  Cell culture growth  
 
Cell culture growth of E. coli XL1-Blue cells with 6T recombinant vector, was followed by 
measuring the absorbance at 610nm for 30 hour after inoculation of 1L of tryptic soy broth medium 
(Table 2.1.2.1) (Biokar, France) containing 100mM ampicillin at 37°C, under agitation (250 rpm).  
 
Table 2.1.2.1 - Tryptic soy broth composition (Sterilized at 121ºC, 20min) 
For 1 L of medium:  
- Tryptone ............................................................................................................... 17.0 g  
- Papaic digest of soybean meal ............................................................................. 3.0 g  
- Glucose ................................................................................................................. 2.5 g  
- Dipotassium phosphate ........................................................................................ 2.5 g  
- Sodium chloride.................................................................................................... 5.0 g  
pH of the ready-to-use medium at 25°C: 7.3±0.2. 
 
 
2.1.3.  Optimization of production conditions of 6T recombinant protein  
 
E. coli XL-1 Blue expressing 6T recombinant protein was cultivated in agitated flasks with 
tryptic soy broth culture medium containing 100 mM of ampicillin and cultivated at 37 ºC after 
induction with isopropyl b-D-1-thiogalactopyranoside (IPTG) collecting samples for 1h, 2h and 3h. 
The final concentration of IPTG added in culture medium was 1 mM. 
The expression of 6T protein was evaluated by SDS-PAGE and western blot using anti-His 
antibody, after cell homogenization in denaturing buffer (8 M urea at pH 8.00). 
 
 
2.1.4.  6T recombinant protein purification  
 
The expression of recombinant protein was carried out as follows. E. coli XL-1 Blue transformed 
using pQE30-6T plasmid was grown at 37ºC, after 3 hours of induction with IPTG, in 2 L of culture 
media, overnight, until mid-log phase (Abs610nm=0.600). Cells were harvested, washed with ice-cold 
10 mM phosphate buffer, pH 7.4 and frozen for further use. For each assay, 1 g (wet weight) of cell 
pellet was resuspended in 10 mL lysing buffer (8M urea, 50 mM sodium phosphate, 500 mM NaCl, 
1% (v/v) Triton X-100, 30 mM Imidazole, pH 8.0) and homogenized with an ultrasound probe for 3 
cycles of sonication for 5 min. each, for cells lysis. Insoluble material was separated by centrifugation 
at 30,000g for 30 min at 4 ºC (Beckman 64R, USA). The supernatant was purified in a HisTrap FF 1 
mL column (GE Healthcare) using a manual method as follows: 
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The protein was loaded onto the column twice times and washed with 10 bed column volumes of 
a solution containing 8M urea, 50 mM sodium phosphate, 500 mM NaCl, 1% (v/v) Triton X-100, 30 
mM Imidazole, pH 8.0. Bound proteins were eluted with 8M urea, 20 mM sodium phosphate, 500 mM 
NaCl, 1% (v/ v) Triton X-100, 250 mM Imidazole, pH 8.0 solution. The eluted proteins were analyzed 
by 10% (w/v) SDS–PAGE under reduced conditions, by western blot using anti-His antibody 
following the NuPAGE Novex Bis-Tris Mini Gels Technical Guide (Invitrogen, UK) and further 
quantified by the BCA Protein Assay kit (Pierce, USA) using BSA as standard. 
The purified protein from the 2.5 mL nickel column was desalted on Sephadex G-25 medium 
pre-filled PD-10 column (GE Healthcare) using 100 mM Heppes buffer pH 7.4.  
Samples taken along the purification steps were analyzed in 10% SDS-PAGE gel followed by 
Western Blot to confirm the presence of recombinant protein in different solutions filtered. 
After this process, the obtained proteins are frozen with 10% of trealose and then lyophilized. 
This was the protein used in in vivo assays and ELISA analysis. 
 
 
2.1.5.  SDS-PAGE 
 
To confirm the presence and the structural integrity of proteins extracted and purified, the 
samples were analyzed by electrophoresis in pre-casted 10% (w/v) polyacrylamide gel (NuPAGE®, 
Invitrogen, UK) and run at a constant voltage of 200 V for 35 min using a Electrophoresis Power 
supply EPS 3501XL system (GE Healthcare Life Science, USA) under denaturing conditions, through 
comparison with BenchMarckTM pre-stained molecular markers in the range of 6-180 kDa (Invitrogen, 
UK) and purified proteins. After migration, proteins were visualized by SimplyBlueTM SafeStain 
solution (Invitrogen, UK). 
 
 
2.1.6.  Western Blotting 
 
Samples were transferred from polyacrylamide gel onto the PVDF membrane using a semi-dry 
transfer system (Hoefer Semiphor Amersham, GE Healthcare Life Science, USA) for 1 h at 0.8 
mA/cm2 membrane. The membrane was then washed and blocked by its incubation with 10% (w/v) 
skimmed milk powder (Merck KGaA, Germany) dissolved in 10 mM PBS at pH 7.4 containing 0.05% 
(v/v) of Tween 20 (PBST; Sigma Aldrich, Co., Germany), for 1 h under constant agitation in an orbital 
shaker (100 rpm). The membrane was further incubated for 2 h at room temperature with mouse anti-
6XHis tag protein diluted in the blocking buffer (1:1700), under constant agitation. After washing, the 
membrane was incubated with a goat anti-mouse IgG conjugated to phosphatase alkaline (Sigma 
Aldrich Co., Germany), diluted 1:2000 in blocking buffer for 1 h at room temperature. The capacity of 
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anti-mouse 6XHis tag protein to recognize the recombinant 6T protein was revealed calorimetrically 
using the substrate kit of alkaline phosphatase SIGMA FAST™ BCIP (5-bromo-4-chloro-3'-
indolyphosphate p-toluidine salt) and NBT (nitro-blue tetrazolium chloride) (Sigma Aldrich, 
Germany), in accordance to the kit instructions.  
 
 
2.1.7.  Protein quantification 
 
The protein quantification was made by BCA (bicinchoninic acid assay), using bovine serum 
albumin (BSA) 1mg/ml as standard protein. Successive dilutions were made in 96-well plates of 1:2 
using bicinchoninic acid and the plates were incubated 1hour at 37ºC.  The BCA protein assay is based 
on the reduction of Cu2+ to Cu1+ by protein in an alkaline medium. The Cu1+ ion reacts with 
bicinchoninic acid forming an intense purple-coloured reaction product. The absorbances are detected 
at 565nm with increasing protein concentration in spectrophotometer (Infinite M200, Tecan, Austria) 
and the absorbance values obtained compared with the standard curve of BSA protein standard in 
order to calculate the protein concentration in mg/ml of sample.  
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2.1.8.  DNA Plasmid extraction and purification 
 
Recombinant 6T-plasmid E. coli strain was inoculated in 1 
L of tryptic soy broth medium (Biokar, France) with 100mM 
kanamycin, at 37ºC/250 rpm until 10h of growth, which 
typically corresponds to the transition from logarithmic into 
stationary growth phase. Cells were isolated by centrifugation 
and cell pellet washed with phosphate buffer saline at pH 7.4 
(10 mM PBS, Invitrogen, UK). The pDNA extraction and 
purification was performed according to the procedure of 
Mega QIAfilter Plasmid purification kit (QIAGEN Inc., 
Germany) as shown in Figure 2.1.8.1. This protocol is based 
on an alkaline lysis followed by vacuum filtration to clear 
bacterial lysates to allow binding of plasmid DNA to 
QIAGEN anion-exchange resin. The RNA, proteins and low 
molecular weight particles are first removed by washing using 
gravity flow. Plasmid DNA is eluted in a high salt buffer. 
Desalting is performed using isopropanol precipitation.  
 
 
2.1.9.  Electrophoresis  
 
To confirm the presence of extracted plasmid DNA, 
samples collected throughout the purification steps were run 
in 1% agarose gel containing ethidium bromide. The gel is 
constituted by 1% of agarose dissolved by heating in TAE 1X 
buffer (1,14 mL glacial acetic acid; 2mL 0.5M EDTA and 4.8 
g/L Tris-base, pH 8.0). To this solution was added ethidium 
bromide (0.3 µg/µl) and the samples were run at constant 
voltage of 60 V.  
 
 
 
 
 
 
 
Figure 2.1.8.1 – QIAfilter Plasmid Kits procedure. 
Adapted from “QIAfilter Plasmid Purification 
Handbook” of QIAGEN Inc, Germany. 
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2.1.10.  Quantification of plasmid DNA 
 
The quantification of purified plasmid DNA was performed using the Quant-iT™ Picogreen® 
assay kit (Molecula Probes™, Invitrogen, UK) according the manual instructions (PicoGreen® 
dsDNA Quantitation Reagent and Kits).  
A serial dilution of the stock DNA standard solution with TE buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH 7.5) was performed yielding eight concentrations ranging from 0.015 µg/mL to 2 µg/mL. 
The samples were also serial diluted. Aliquots (100 µL) of each preparation, standard and samples, 
was placed in duplicate into a white 96-well plate (Griner, Germany) for measurement. The working 
PicoGreen® reagent (100 µL) was added to each measurement well. The blank solution was prepared 
identically, but without DNA. The prepared 96-well plate was incubated for 5 min at room 
temperature, and fuorescence was measured in a fluorescence microplate reader (Infinite M200, 
Tecan, Austria) at 480 nm excitation wavelength and 520 nm emission wavelength. The average value 
of blank measurement was subtracted from the duplicate measurements made at each standard 
concentration. The results were plotted and a linear regression was performed on the standard curve to 
calculate the DNA concentration in each sample.   
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2.2.  In vivo Assays 
 
2.2.1.  Nanoparticle preparation 
 
For intramuscular (i.m.) immunisation, recombinant protein or plasmid were encapsulated in 
chitosan/sodium deoxycholate (CS/DS) (1:1 w/w) nanoparticles. These were prepared using an 
ionotropic gelation technique, previously described by Cadete et al. (2012). Briefly, chitosan and 
sodium deoxycholate were separately dissolved in ultra-pure water in order to obtain 1mg/mL 
solution. Nanoparticles were formed when 1 volume of DS solution was added drop wise to one 
volume of CS solution and magnetically stirred at 300 rpm for 15 min at room temperature. For the 
nanoencapsulation, pDNA and protein was added to DS solution before the addition to CS solution.  
 
For oral vaccination the antigens, recombinant protein or plasmid, were encapsulated in 
chitosan/tripolyphosphate/alginate (CS/TPP/Alg) (20:0.25:1 w/w/w) nanoparticles. These were 
prepared using thr ionotropic gelation technique previously described in Gonçalves et al. (2011). 
Briefly, chitosan (low molecular weight), sodium tripolyphosphate and sodium alginate (low 
viscosity) were separately dissolved in ultrapurified water in order to obtain respectively 2.5mg/mL, 
10mg/mL and 3 mg/mL solutions. The alginate solution was added to the TPP and this was added drop 
wise to the chitosan solution. For encapsulation the solution of recombinant protein or plasmid was 
added to TPP/Alg solution before the addition to CS solution.  
 
 
2.2.2.  Immunization studies / Vaccination 
 
Ten groups of female BALB/c mice (n=5/group), were used in the in vivo studies, which were 
performed in strict accordance with the Directive of 24 November (mº86/609 EEC), the Portuguese 
laws D.R. nº 31/92, D.R. 153 I-A 67/92 and all following legislation.  
Mice were immunized on day 1 and boosted on day 22, either by the oral or the i.m. routes, with 
50 µg of encapsulated protein and/or pDNA . Controls were administrated with equivalent doses of 
non-encapsulated protein and DNA, with empty nanoparticles and PBS. All doses were freshly 
prepared in sterile PBS (pH 7.4) under aseptic conditions, just before animal dosing and boosting. 
Group 1 received encapsulated pDNA by the oral route; Group 2 received free pDNA (in solution) by 
the oral route; Group 3 received encapsulated recombinant protein by the oral route; Group 4 received 
free protein (in solution) by the oral route; Group 5 received encapsulated pDNA by the i.m. route; 
Group 6 received free pDNA (in solution) by i.m. route; Group 7 received encapsulated recombinant 
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protein  by i.m. route; Group 8 received free recombinant protein (in solution) by i.m. route; Group 9 
was vaccinated with empty nanoparticles by i.m. route ; Group 10 received PBS (table 2.2.2.1). 
 
Table 2.2.2.1 - Immunization groups with recombinant antigens 6T and 6T-plasmid by oral 
and i.m. routes. 
Groups Antigens 
Dose/presentation 
antigen 
Via 
1 
6T-plasmid encapsulated in 
CS/TPP/alginate nanoparticles 
2x50µg/encapsulated 
Oral 
2 6T-plasmid in solution 2x50µg /free 
3 
6T recombinant protein 
encapsulated in CS/TPP/alginate 
nanoparticles 
2x50µg /encapsulated 
4 
6T recombinant protein in 
solution 
2x50µg /free 
5 
6T-plasmid encapsulated in 
CS/DS nanoparticles 
2x50µg /encapsulated 
i.m. 
6 6T-plasmid in solution 2x50µg /free 
7 
6T recombinant protein 
encapsulated in CS/DS 
nanoparticles 
2x50µg /encapsulated 
8 
6T recombinant protein in 
solution 
2x50µg /free 
9 CS/DS empty nanoparticles Empty nanoparticles 
10 Naive Naive 
_____ 
 
 
2.2.3.  Sample collection and analysis 
 
Blood samples of each mouse were collected every two weeks from the tail vein after the first 
immunization, during 4 months. Blood samples were centrifuged at 18,000×g for 20 min at 4ºC and 
serum was collected and stored at -20ºC until analysis (Figure 2.2.3.1). The serum antibody levels 
were determined by an enzyme-linked immunosorbent assay (ELISA) using purified 6T recombinant 
proteins (described in section 2.1.).  
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To quantify the cytokines production and the mucosal immune response, spleens and intestines 
were collected (Figure 2.2.3.1), from ethically sacrificed animals according to a previously described 
method (Figueiredo et al., 2012a). 
 
Figure 2.2.3.1 – Sample collection and immunoassays scheme. After oral and i.m. immunization, 
blood samples were collected every 2 weeks, and antibody titres measured by ELISA. Spleens and 
intestines were collected for determination of specific IgA and specific cytokine titres using specific 
ELISA techniques.  
 
 
2.2.4.  Quantification of immune response by ELISA  
 
The antibody responses (IgG, IgG1 and IgG2a) to recombinant protein (6T) and plasmid (6T-
plasmid) were determined according to a previously reported method (Figueiredo et al, 2012a). ELISA 
plates (Microlon®, High binding flat bottom plates, Greiner, Germany) were coated overnight with 5.0 
µg/mL 6T recombinant protein enzymatic in 100 mM sodium carbonate buffer (pH 9.6), washed and 
afterwards blocked with a 5% (w/v) skimmed milk powder (Merck KGaA, Germany) dissolved in 10 
mM PBS, pH 7.4 containing 0.05% (v/v) of Tween® 20 (PBST; Sigma Aldrich, Co., Germany). Plates 
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were washed again and sera were tested by serial two-fold dilutions. Sera obtained from naive mice 
were used as a control. Horseradish peroxide conjugate goat anti-mouse IgG, (Sigma, Pool Dorset, 
UK), IgG1 and IgG2a (Serotec, UK) (diluted 1:1000) were applied as secondary antibody. 
Finally, the substrate OPD (SigmaFAST™ OPD Kit, Sigma Aldrich, Germany) was used to 
develop the plates, the colour reaction was stopped after 15 min by adding 2.5N H2SO4 to the wells, 
and absorbance was read at 490 nm.  
For analysis of intestine IgA, the ELISA method was essentially the same, with some 
modifications. The intestines were homogenized in 0.9% sodium chloride with protease inhibitor 
PMSF 1 mM and 0.5% Tween® 20. The homogenization was performed using an ultrasound probe (3 
× 5 min intermittent pulsed for 30 s each, in an ice bath). The homogenized tissues were centrifuged at 
20,000×g for 30 minutes, at 4ºC (Allegra 64R, Beckman, USA), and the supernatant was frozen at 
−80ºC until freeze-drying. After freeze-drying, proteins were reconstituted with 500 µL of sterile 
water and added directly, in triplicates, to the plate wells. The horseradish peroxide conjugate goat 
anti-mouse IgA (1:2000; Serotec, UK) was used to detect this antibody and OPD substrate was then 
added as mentioned above. The mean OD was determined for each treatment group and used directly 
to compare mucosal response. The titres reported are the reciprocal of serum dilutions that gave an 
optical density 5% higher than the strongest negative control reading.  
 
 
2.2.5.  Cytokine production studies 
 
Mice were sacrificed and spleens were aseptically collected into test tubes containing RPMI 
medium (Gibco, UK). After washing with RPMI medium, spleens were transferred to RPMI complete 
medium (RPMI culture medium supplemented with 10% fetal bovine serum (FBS), 20mM L-
glutamine, 105U/L penicillin and 100mg/L streptomycin) and spleen cells were dispersed with the aid 
of two needles. Cell suspension was centrifuged at 200×g for 10 min and the pellet resuspended in 
RPMI complete medium to perform another centrifugation. Cells were counted in a haemocytometer 
diluted in trypan blue and the cell concentration was adjusted to 2x106/100µL in RPMI complete 
medium. Aliquots of 100 µL of cell suspension were added to each well of a cell culture plate 
(Greiner, Germany) containing 100 µL of RPMI complete medium and other plate containing 100 µL 
of RPMI complete medium with 5 µg/mL of antigen (6T). Plates were incubated in 5% (v/v) CO2 
incubator for 72 h at 37ºC. Supernatant was collected and stored at -80ºC for subsequent analysis. 
Cytokines IL-2, IL4, IL-6 and IFN-γ were then quantified using appropriate kits: Mouse IL-2 ELISA 
Kit, Mouse IL-4 ELISA Kit, Mouse IL-6 ELISA Kit and Mouse IFN-γ ELISA Kit (RayBiotech, 
USA). 
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2.2.6.  Statistical analysis 
 
Results are expressed as mean±standard deviation (SD). The results of animal experiments are 
presented as mean ± standard error of the mean (SEM). Statistical analysis of the experimental data 
was performed using the nonparametric Mann-Whitney test and significance was defined for p value 
<0.05. 
 
 
2.3. Agglutination assays 
 
In this study, nine H. pylori strains from the collection of the National Institute of Health Dr. 
Ricardo Jorge (Lisbon, Portugal), primary isolates from Portuguese colonized patients, were 
inoculated in Brucella agar medium plates (Table 2.3.1) at 37ºC under microaerophilic environment 
(CampyGen; Oxoid, Hampshire, UK) for approximately 48 hours. Agglutination tests were then 
performed with these strains and sera from immunised mice to checking for the presence of 
neutralising antibodies.  
 
 
Table 2.3.1 – H. pylori selective medium composition (per litre) 
Agar 17g 
Brucella broth (BB) 28g 
Fetal Bovino Serum (FBS) 50 mL 
 
 
Agglutination tests were performed according with the BSOP TP 3 as issued by Standards Unit, 
Department for Evaluations, Standards and Training, UK. Briefly, all bacteria were tested after total 
biomass was recovered from the growth plates with a 10-3 ml plastic loop and resuspended in 200µL of 
PBS (pH 7.2). Twenty µL of bacterial suspension were placed on glass slides, against black 
background, and 10 µL of serum were added followed by homogenization. Each serum was diluted 
1:10 and 1:40 and each dilution was tested with each H. pylori strain. Negative controls were 
performed with 20 µL of bacterial suspension only. Agglutinations were graded as follows: (+) 
agglutination observed, (-) no agglutination observed and (?) inconclusive observation. 
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3.1.  Antigen production 
 
3.1.1. Cell transformation 
 
E. coli XL1-Blue cells were transformed with two plasmids pQE30 (6T) and pVAX1 (6T-
plasmid). The genetic sequence cloned into the plasmid vectors, coding for the recombinant proteins 
and pDNA, contains the immunogenic and conserved sequences of the following H. pylori antigens: 
CagA, UreB, HpaA, VacA, GroEL and Homb. It was demonstrated that H. pylori vaccines comprising 
a single recombinant antigen were only partially effective (Liu et al., 2011). Therefore, it is thought 
that effective immunity against H. pylori infections could be achieved by a combination of various 
antigens involved in the pathogenesis of infection. So fragments of these six different antigens of H. 
pylori were chosen as candidate antigens to vaccine design in order to confer protective 
immunogenicity against infections of a large range of H. pylori strains. These six fragments of 
antigens were selected based on an extensive research that is part of an ongoing research project. Due 
to intellectual property constraints the sequences and the methods used to obtain the genetic constructs 
cannot be fully described herein. Nevertheless, its description remains beyond the scope of this 
dissertation. 
The plasmid vectors pQE30 (6T) is a prokaryotic vector that allows protein expression in 
prokaryotic cells, whereas pVAX1 (6T-plasmid) is a eukaryotic vector under the promoter of 
cytomegalovirus that permits the expression of the protein antigen in host eukaryotic cells, in order to 
facilitate the induction of cellular immunity (Zhang et al., 2003). 
 
 
3.1.2.  Cell culture growth 
 
The successful expression of recombinant proteins in E. coli depends on the optimization of the 
methods used. Optimization of the protein expression is essential for the maximization of protein-
yield, for successful expression and for protein integrity.  
Previous studies have indicated that the time of induction is important for optimal expression of a 
cloned gene. It is also important to control growth phases of E. coli culture for inferring the beginning 
of exponential phase, because it is in the early exponential phase that cell growth starts, more nutrients 
are available and thus more protein will be expressed. An early induction of protein expression at lag 
phase can lead to up to 50% inhibition of biomass production. Existing no recipes or formulas for 
optimal expression of proteins, it is necessary to optimize the best protocol for each protein and for 
each culture (Olaofe et al., 2010). 
In order to determine the stage of cell cultivation suitable for optimal expression of recombinant 
proteins, E. coli 6T culture in shack flask was incubated at 37ºC. Sampling was performed every hour 
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and the culture growth was followed by measuring the optical density at 610 nm over 30 h of 
incubation (Figure 3.1.2.1). 
 
 
Figure 3.1.2.1 – Cell growth curve of E. coli XL1 Blue expressing 6T recombinant protein. Arrow 
indicates the time of IPTG addition. 
 
Through the growth curve we are able to confirm that after five hours of incubation culture begins 
the exponential grow, where the OD610nm is 0.600 as shown in Figure 3.1.2.1.At this stage, the cells 
initiate a period of exponential cell division and consequently initiate protein synthesis. According to 
Olaofe et al. (2010), the early exponential phase is the best time to induce protein expression. After 10 
hours of incubation the bacterial culture reaches the stationary phase, stabilizing the cell growth.   
 
 
3.1.3.  Optimization of protein expression conditions 
 
The expression of recombinant proteins in cells in which they do not naturally occur is termed 
heterologous protein production (Weng et al., 2006).  Protein concentration increased by a factor of 
approximately two with IPTG addition in early exponential phase compared to cultures without 
inducer (Olaofe et al., 2010). For this reason recombinant protein expression was performed by 
addition of isopropyl-beta-D-thiogalactopyranoside (IPTG) to a final concentration of 1mM after five 
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hours of culture incubation when OD610=0.600. The aim is to optimize a feeding induction protocol for 
protein expression by host strain. 
The IPGT, an analogue of lactose, is an inductor of genetic 
transcription which when added to the cell culture increase synthesis 
of T5 RNA polymerase enzyme, which binds to the T5 promoter 
initiating the expression of the cDNA of interest (figure 3.1.3.1). 
The promoter system of T5 RNA polymerase is the most efficient 
prokaryotic system, heavily regulated, allowing only the expression 
of recombinant protein with T5 promoter when added IPTG and 
allowing high levels of expression (Weng et al., 2006).  
Our aim was to empirically optimize expression protocol for 
our 6T host strain. So in order to evaluate which incubation time is 
required after IPTG addition, to maximize the recombinant proteins 
synthesis, samples were taken over 3 hours (time 0, 1, 2 and 3) post-induction. These samples were 
then analysed by SDS-PAGE and Western Blot (Figure 3.1.3.2).  
From the results obtained (Figure 3.1.3.2) it can be observed a band of approximately 49 kDa 
similar in size to 6T recombinant protein, since this protein has a molecular mass of 47kDa. Western 
Blot analysis confirmed a signal sequence at ~49kDa that corresponding to 6T recombinant protein. 
The six histidines tagged to 6T recombinant proteins act as an protein epitope detected by anti-HistTag 
antibodies in Western Blot (Ramos et al., 2004). It indicates that there was induction and expression of 
the desired 6T-protein successfully. The 115kDa bands observed in SDS-PAGE and in Western Blot 
correspond to the insoluble fraction of the expressed protein. Both soluble and insoluble fractions of 
the protein were expressed and can be use as antigens for vaccine formulation, since they retain their 
immunogenicity. 
After induction (T1, T2 and T3), the intensity of the 49 kDa and 115 kDa bands increased over 
time, suggesting the quantity of protein expressed increases over time, stabilizing after 3 hours of 
induction with IPTG, without significant differences in the amount of protein expressed, as compared 
to T2. 
At time zero (T0) a basal expression of the 6T proteins is detected. These proteins are highly 
regulated by T5 promoter with the induction of IPTG, but might be activated by other pathways 
(Weng et al., 2006). 
 
Figura 3.1.3.1 – Expression system 
of pQE30 recombinante proteins 
induced by IPTG. 
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Figure 3.1.3.2 - SDS-PAGE and Western Blot of 6T-protein extract processed with anti-HistTag 
antibodies. MW – pre-stained Molecular Weight Markers; T0 – sample before induction with IPTG; 
T1 – sample after 1 hour of induction with IPTG; T2 - sample after 2 hours of induction with IPTG; 
T3 - sample after 3 hours of induction with IPTG. 
 
The induction of recombinant protein expression usually results in impaired growth rates and low 
increase in cell mass (Sorensen and Mortensen, 2005), which correlates inversely with the rate of 
synthesis of recombinant proteins. Hence, expression for longer times would not be advantageous 
because the growth rate of cells expressing proteins decreases over time, leading to stagnation of rates 
of specific protein expression and reducing process productivity (Teich et al., 1998). This is due to the 
fact that expression of proteins stops when cell growth reaches the stationary phase and nutrient 
concentration decreases, thus greatly reducing cell division and protein expression (Olaofe et al., 
2010). 
Taking into account the results obtained for maximizing the expression of recombinant proteins, 
the ideal incubation time after induction with IPTG is 3 hours. 
 
 
3.1.4.  Protein purification 
 
The pQE30 plasmid expressing recombinant 6T protein permits rapid protein purification through 
a 6XHis-tag fused to the expressed proteins, which has affinity to the nickel-affinity chromatography 
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column. Affinity chromatography allows to recover proteins with a purity level higher than 95% 
(Terpe, 2003). Histidine-Tag is the preferred purification system for protein purification, especially 
when knowledge of the biochemical properties of the protein is poor (Arnau et al., 2011), just as in 
this case. It allows easy purification and specific detection of recombinant proteins by immunological 
methods such as Western Blot. Other advantage of Hist-Tag, described by Ramos et al. (2004) and 
Catanzariti et al. (2004), is that fusion proteins can be purified under denaturing conditions since the 
interaction between consecutive histidine residues and the affinity nickel column is stable in 8 M urea, 
which is a strong protein denaturant. In the case of recombinant 6T-protein, the protein refolding is not 
essential since it is not necessary to maintain protein function. Only epitopes immunogenicity has to 
be maintained and displayed upon antigenic presentation. Purification in denaturing conditions allows 
increasing protein purity because it permits a better exposure of HistTag at the protein surface, while 
decreasing protein aggregation (Triccas et al., 1998; Terpe, 2003).  
After 3 hours of induction of protein expression with IPTG 1mM, the culture was centrifuged and 
lysed. Expressed proteins were purified through immobilized metal ion affinity chromatography 
(IMAC) in Hist Trap FF 1mL nickel column (GE Healthcare, England). Six consecutive histidine 
residues tagged to the recombinant proteins allow specific binding of the histidine to metallic ligands, 
such as nickel, retaining the protein in the column. This procedure was performed in denaturing 
conditions, since the buffers used during purification contain 8M Urea. 
The SDS-PAGE and Western Blot were used to analyse the samples from the recombinant 
protein purification and identification process, using specific anti-histidine antibodies (Figure 3.1.4.1). 
Western Blot confirmed a signal sequence at ~49 kDa that corresponds to the 6T recombinant protein 
(MW 47 kDa). Is also revealed a 115 kDa band, corresponding to the insoluble fraction of the 
recombinant protein expressed. Overproduction of heterologous proteins in E. coli could lead to 
misfolding and segregation into insoluble aggregates known as inclusion bodies. Another reason is the 
linking of histidine tails with each other forming agglomerates of proteins. Even under denaturing 
conditions (8 M Urea) these aggregates are difficult to eliminate, as observed in 115 kDa band. 
Accordingly Han et al. (2011), the high-level of expressed inclusion bodies may also be useful for 
purification because aggregates are easily isolated due to the histidine-tag located at the protein 
surface, and formation of inclusion bodies protects the protein from proteolytic attack. In this case, 6T 
protein does not need to be soluble and retains its function, as long as it can be used directly as an 
antigen since it retains its immunogenicity.  
Flow-through sample, analysed in line F of Figure 3.1.4.1, shows a large amount of other proteins 
extracted from the bacteria, but there was no corresponding specific reaction at ~47 kDa with anti-
histidine antibodies in western blot. Therefore, protein degradation or premature translation product at 
lower molecular weights may also occur since they cannot be detected by Western Blot. Degraded 
proteins were not retained in the column, since plenty is found in flow-through solution but are absent 
in wash solution (W). The column was washed with Binding buffer with low concentrations of 
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imidazole (30mM) for cleaning up non-specific binding proteins and minimizing binding host cell 
proteins. Low imidazole concentrations permits minimizing nonspecific binding host cell proteins and 
other impurities present in cell lysate (Terpe, 2003). In Figure 3.1.4.1, line W suggests that part of 6T-
protein is released from the column during the washing step, because imidazole competes with 
proteins for binding to the nickel, so  imidazole itself may have impaired the binding of some 6T-
proteins leading to their release. Future optimization of the imidazole concentration will have to be 
performed for improving the amount of histidine-tagged purified protein. Thus, the optimized 
imidazole concentration ensures the best high purity (low binding of others proteins) / high yield 
(strong binding of histidine-tagged proteins) balance (Terpe, 2003). 
The histidine-tagged proteins retained in the nickel column were eluted with Elution buffer 
containing high imidazole concentrations (250mM). As imidazole and histidine contain a similar 
radical, high concentrations of imidazole allow, by competition, the release of histidine-tagged 
proteins bound to the column (Terpe, 2003). Figure 3.1.4.1 shows strong bands at ~47 kDa and 
~115kDa molecular weights, indicating 6T proteins were successfully purified and the purity level 
increases along the 3 elutions, since no other contaminants are detected in Western Blot (E2 and E3 
samples).  
 
 
Figure 3.1.4.1 –SDS-PAGE (10% polyacrylamide gel) and Western Blot of samples from purification 
process of recombinant 6T protein. (MW- molecular weight standards; F – Flow-through sample; W – 
wash sample; E1 – first elution sample; E2 – second elution sample; E3 – third elution sample). 
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Some protein was lost during the purification process. However it was possible to purify the 
desired 6T-proteins with high degree of purity by affinity chromatography. Therefore, nickel-affinity 
chromatography enables a strong adsorption onto the stationary phase, allowing an efficient removal 
of other components before the protein is desorbed from the column, as well as a high yield of 
purification of the desired protein (Han et al., 2007; Arnau et al., 2011). 
After affinity chromatography the protein is in a denaturing buffer containing 8M urea and 
250mM of imidazole, thus a new step was needed for buffer exchange. The buffer exchange was 
performed through PD-10 desalting column containing Sephadex G-25 Medium (GE Healthcare, 
EUA), which allows separation of substances with high molecular weight (Mr=5000 Da) from 
substances with low molecular mass (Mr=1000 Da). The PD-10 desalting column was used to separate 
small molecules such as salt and other impurities, from the proteins of interest. Molecules smaller than 
the largest pores in the Sephadex matrix will be retained within the pores, therefore are eluted after the 
large molecules. The purified proteins are eventually diluted whenever it is desalted. Protein recovery 
was made using 100mM HEPES buffer. This buffer is more effective in maintaining protein structure 
at low temperatures and in maintaining pH levels during freeze drying, to prevent protein denaturation.  
The protein was quantified before and after desalting using the BCA method, taking into account 
that 2.5 mL of protein applied to the column PD-10 is eluted with 3.5 mL of the new buffer solution 
(dilution factor of 1.75 fold). So, BCA method (section 2.1.7.) is based on the conversion of Cu2+ to 
Cu
+
 under alkaline conditions. The Cu
+
 is then detected by reaction with BCA. Since BCA is stable 
under alkaline conditions, this assay has the advantage of being carried out as a one-step process. This 
reaction results in the development of an intense purple colour, detected at 565nm of absorbance. 
Since the production of Cu+ is a function of protein concentration, this may be determined 
spectrophotometrically by comparison with known amounts of standard proteins (Krieg et al., 2005; 
Walker, 2009). 
In this study, the BCA assay has the advantage of being unaffected by denaturing agents such as 
urea (Walker, 2009), so it is suitable for quantifying 6T purified protein in 8 M Urea.  
 
Table 3.1.5.1 – Amounts of purified protein obtained before and after buffer exchange and desalting.  
Buffer Protein Concentration (µg/mL) 
Total Protein (µg/g 
cells wet weight) 
8M Urea 310 4.655 
100mM Hepes 129 2.714 
Yield 58% 
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There was protein lost during the desalting with PD-10 column (Table 3.1.5.1) and the yield of 
this step of purification was 58% (w/w). 
 
 
3.1.5.  Plasmid DNA purification  
 
Large-scale produced pDNA must be available for vaccine formulation as a highly purified 
molecule, without any traces of RNA, endotoxins and proteins. Accordingly, anion-exchange 
chromatography provides a good selectivity for pDNA purification in the presence of RNA, 
endotoxins and residual protein (Stadler et al., 2004). 
In order to determine the plasmid yield after purification, samples were collected during the 
plasmid DNA purification procedure and analysed by electrophoresis in 1% agarose gel stained with 
ethidium bromide (Figure 3.1.6.1). The size of plasmid DNA determines the gel migration pattern, but 
there are other factors that may influence this pattern. Plasmid DNA, under some conditions, can 
assume others isoforms such as super coiled form that tends to migrate faster than circular plasmid 
DNA.  
Figure 3.1.6.1 shows a filtered lysate (A1) containing supercoiled and open circular plasmid 
DNA, as expected, and others isoforms of supercoiled plasmid DNA; a flow-through fraction (A2) 
containing slight bands corresponding to different isoforms of pDNA that not bind to the QIAGEN 
Resin; a fraction (A3) after washing the QIAGEN resin with a specific buffer to remove all 
contaminants. It is evident that there was no DNA loss during this process since no band is observed 
and that pDNA is pure without any contaminants. The A4 sample corresponds to the elution fraction 
of DNA before being precipitated with isopropanol. Only after being precipitated, DNA is observed in 
electrophoresis gel and therefore is not seen in A4 sample in agarose gel. Lastly, Figure 3.1.6.1 shows 
the samples taken after purified DNA precipitation with isopropanol (A5 and A6), presenting strong 
bands at 4.0 kb and at 2.0 kb, which correspond to recombinant 6T-plasmid at circular form and super 
coiled, respectively. The intensity of emitted fluorescence, that was proportional to the amount of 
DNA, we can confirm that after purification we obtained a large amount of plasmid DNA purified 
with success in both circular and supercoiled form. In this study, supercoiled pDNA could be more 
advantageous for a more efficient uptake and higher transfection of host cells.  
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Figure 3.1.6.1 – Confirmation of the purification of plasmid DNA by agarose gel electrophoresis. DL 
- DNA ladder containing the molecular weight standards; A1 – sample of cleared lysate; A2 – sample 
from the flow-through faction; A3 – sample from washing; A4 – sample from the eluate; A5 – sample 
obtained after precipitation with isopropanol; A6 – sample obtained after washing with 70% ethanol.  
 
 
Quant-iTTM Picogreen® dsDNA, a fluorochrome that selectively binds dsDNA, which becomes 
intensely flourescent upon binding double-stranded DNA in solution, was used for plasmid DNA 
quantification. The brightness of this reagent is due to its high quantum yield and large molar 
extinction coefficient (Singer et al., 1997).  
In order to calculate the amount of plasmid DNA extracted and purified, to subsequent 
encapsulation and vaccine production, a Picogreen® assay kit was used according to the manual 
instructions. The amount of purified 6T-plasmid precipitated after centrifugation and afterwards 
redissolved from tube walls (plasmid residual) was quantified. 
 
Table 3.1.7.1 – Total amount of purified 6T-plasmid. 
[plasmid] 1769µg/mL 
[plasmid]residual 648 µg/mL 
Total [plasmid] 285.5 µg/ g cell wet weight  
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3.2. In vivo assays 
 
Several prophylactic vaccines against H. pylori infection have been developed but have failed to 
confer protective immunity or eliminate an ongoing infection by H. pylori (Algood and Cover, 2006; 
Zhou et al., 2009; Velin and Michetti, 2010; Liu et al., 2011). Accordingly, it was thought that a 
multi-epitope vaccine based in both DNA and recombinant protein as antigens could bring advantages 
and confer effective protection against H. pylori infection.  
Here we present our initial findings on the efficacy of this construct as a prophylactic vaccine in a 
mouse model. 
 
 
3.2.1. Nanoparticle characterization  
The delivery of nanoparticles by oral route involves overcoming several physiological barriers 
such as enzymatic degradation, low gastric pH, crossing the mucus layer and cellular uptake. 
To overcome these barriers, chitosan nanoparticles appear as promising oral drug carrier system, 
due to its mucoadhesive properties. Such bioadhesiveness will enable a higher interaction between the 
carrier nanoparticle and the membrane epithelium, allowing a more effective uptake and transfection 
of the antigens (Aebischer et al., 2010; Gonçalves et al., 2011; Cadete et al., 2012). 
Chitosan binds to cell membranes, promoting transcellular and paracellular permeability showing 
high transfection efficiency, and for these reasons it has been used as a biomaterial for non-viral gene 
delivery system (Gonçalves et al., 2011; Cadete et al., 2012). The pDNA encapsulated in chitosan 
nanoparticles are taken up by cells endocytosis, macropinocytosis or phagocytosis in intracellular 
vesicles, where a small fraction of the DNA is released into cytoplasm and migrates into the nucleus, 
and is expressed (Cadete et al., 2012). 
Particle size, DNA and antigen loading, and route of administration are the main characteristics 
that could influence the interaction with mucosal tissues, particle uptake, translocation and transport to 
the lymphatic nodes (Florindo et al., 2009). Four types of nanoparticles were formulated, 
incorporating pDNA or recombinant protein antigens. CS/DS nanoparticles were used for 
intramuscular vaccination and CS/Alg/TPP nanoparticles were used in oral immunization. The 
physicochemical characteristic of nanoparticles were evaluated previously by (Gonçalves et al., 2011) 
and are summarized in Table 3.2.1.1. 
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Table 3.2.1.1 – Charecteristics of nanoparticle used in immunization studies. Values are expressed as 
mean±S.D. (n=3).  
Nanoparticles Mean size (nm) pDNA/CS (w/w) 
Encapsulation 
efficiency (%) 
CS/DS 
pDNA 242 ± 8 32 100 
Protein 894 ± 6 - 70 ± 10 
CS/Alg/TPP 
pDNA 195 ± 1 15 100 
Protein 328 ±7 - 70 ± 8 
 
 
In a previous work (Gonçalves et al., 2011) it has been demonstrated, that chitosan/alginate 
nanoparticles can protect the encapsulated plasmid DNA from nuclease degradation, whereas pDNA is 
degraded when in direct in vitro exposure to the same environment. Moreover, nanoparticles 
containing DNA were able to transfect different cell lines, where high expression of genes was 
achieved, while showing low toxicity levels (Cadete et al., 2012). 
 
 
3.2.2. Immunization studies 
 
In order to measure and evaluate the immune response elicited by recombinant proteins and 
pDNA, BALB/c mice were immunized twice by oral and i.m. routes with recombinant proteins or 
pDNA, either nanoencapsulated or in solution. Animals were treated at day 1 (priming) and boosted at 
day 22 (see Table 2.2.2.1). Throughout the experiment, all immunized mice remained healthy. There 
were no adverse reactions after immunization including lethargy, weight loss, etc. (data not shown). 
Results were restrictively compared using nonparametric Mann-Whitney test. 
As mentioned above (section 1.5.), despite it remains unclear which type of protective immune 
response does confer protection against H. pylori infections, there is consensus that CD4+ T cells are 
essential for this protection (Algood and Cover, 2006; Moss et al., 2011). Interestingly H. pylori 
infections elicit only a Th1 polarized immune response, so the immune system is incapable of 
generating an efficiently balanced immune response. Therefore, it is thought that an effective 
therapeutic vaccine should induce a balanced Th1 and Th2 immune response for successfully eradicate 
H. pylori infections (Suerbaum and Michetti, 2002; Vajdy et al., 2003; Zhou et al., 2009).  
To assess whether administered vaccines are leading or not to a balanced immune response, 
specific IgG isotypes were evaluated in immunised mice. The sera from negative controls (groups 9 
and 10) were used as baseline to obtain the titre values for the treated groups. Two weeks after prime 
vaccination, immunized mice started to produce specific H. pylori IgG types (Figure 3.2.2.1).  
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It is important to point out that boosters at day 22 elicited a significant increase in antibody levels, 
which were maintained at the end of the study for almost all vaccinated groups (Figure 3.2.2.1). 
 
 
Figure 3.2.2.1 - Serum anti-H. pylori specific IgG, IgG1 and IgG2a titres induced after mice 
immunization with: G1 – nanoencapsulated pDNA by oral route; G2 – free pDNA in solution by oral 
route; G3 – nanoencapsulated recombinant protein by oral route; G4 – free recombinant protein in 
solution by oral route; G5 – nanoencapsulated pDNA by i.m. route; G6 – free pDNA in solution by 
i.m. route; G7 – nanoencapsulated recombinant protein by i.m. route; G8 – free recombinant protein in 
solution by i.m. route. Data represent a preliminary assessment concerning serum pool of each group 
(n=5). 
 
Through specific IgG titres the type of response that is being generated can determined, because 
IgG1 is stimulated by a Th2 type immune response, whereas IgG2a is produced in a Th1 type response 
(Peek et al., 2010; Velin and Michetti, 2010). So, high levels of both IgG1 and IgG2a indicate the 
stimulation of a balanced immune response.  
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Figure 3.2.2.2 – Serum anti-H. pylori specific IgG, IgG1 and IgG2a titres induced by immunization 
with pDNA by both oral and i.m. route. Data represent a preliminary assessment concerning serum 
pool of each group (n=5). 
 
It can be observed in Figure 3.2.2.2 that an effective immune response was triggered only by i.m. 
immunization with pDNA-based vaccines. Encapsulated and free pDNA administrated orally (G1 and 
G2) resulted in lower levels of all IgG isotypes when compared with groups immunized i.m., without 
significant differences among both oral groups (p=0.2500) and among Ig2a/IgG1 antibodies rate 
(p=0.1736).  
Significant differences in the response to pDNA administered i.m. (G5 and G6) were found in 
IgG2a/IgG1 rate (p=0.0452). While pDNA in solution induced a strong Th1 response expressed by 
high levels of IgG2a, i.e. similar to immune response induced by natural H. pylori infections with 
inefficient infection elimination, nanoencapsulated pDNA induced a balanced Th1/Th2 immune 
response. This suggests a high immunogenicity of the multi-epitope antigen. In addition, it confirms 
the properties of CS nanoparticules, such as mucoadhesiveness and permeation-enhancement, 
allowing a more effective response through a prolonged interaction with the host cells surface, and 
consequently a high level of DNA transfection to host cells, as showed in Cadete et al. (2009). 
Comparing both administration routes (Figure 3.2.2.2), pDNA encapsulated in chitosan 
nanoparticles administered i.m. showed to induce a higher, balanced and prolonged immune response 
by high levels of specific IgG antibodies. 
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Figure 3.2.2.3 – Serum specific anti-H-pylori IgG, IgG1 and IgG2a titres stimulated by 
immunizations with 6T recombinant protein by oral (G3 and G4) and i.m. route (G7 and G8). Data 
represent a preliminary assessment concerning serum pool of each group (n=5). 
 
 
Data in Figure 3.2.2.3 shows that there were significant differences between oral and i.m. 
immunizations. Recombinant proteins administered by i.m. route elicited a high and balanced immune 
response, confirming the strong potential of these vaccines for protection against H. pylori, as reported 
in previous studies by (Figueiredo et al., 2012b). Other studies have showed the potential of 
intramuscular immunizations as protective (Zhou et al., 2009; Azizi et al., 2010; Liu et al., 2011). 
Oral immunization with these antigens could also induce an immune response with IgG1 
predominance, showing the ability to induce a Th2 polarized response different from those induced by 
natural H. pylori infections. Further studies must be performed to confirm if this Th2 polarized 
response could confer protection against H. pylori infection, because it is controversial whether 
humoral response contributes to protective immunity (Zhou et al., 2009). 
No significant differences were observed between both delivery systems, indicating that 6T 
recombinant protein is highly immunogenic and capable of inducing a strong immune response 
without any delivery system or adjuvant. 
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Figure 3.2.2.4 – Serum specific anti-H. pylori IgG, IgG1 and IgG2a titres from immunized mice with 
pDNA and 6T protein by the oral route. Data represent a preliminary assessment concerning serum 
pool of each group (n=5).  
 
 
After oral immunization only recombinant proteins showed an efficient stimulation of specific 
IgG, IgG1 and IgG2a antibodies, whereas pDNA showed lower IgG isotypes titres. Significant 
differences (p=0.0056) were found between pDNA vaccines and those prepared with H. pylori 
recombinant antigens. These results lead to the conclusion that the nanoparticulate carriers used may 
not be suitable for the hostile environment of the stomach and may undergo degradation by the low pH 
environment and enzymes present in the stomach. 
 
 
Figure 3.2.2.5 – Serum anti-H. pylori specific IgG, IgG1 and IgG2a titres of mice immunized by i.m. 
route, with pDNA and recombinant proteins, both encapsulated and in solution. Data represent a 
preliminary assessment concerning serum pool of each group (n=5). 
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Both i.m. administered nanoencapsulated pDNA and recombinant proteins induced strong Th1 
and Th2 immune responses (Figure 3.2.2.5). Nevertheless, it was observed that recombinant proteins 
elicit a higher and more balanced immune response than that obtained with pDNA. This indicates that 
i.m. route could be a good approach for immunization, inducing of a strong systemic immune response 
by pDNA or recombinant proteins. No significant differences (p=0.8376) were found between 
IgG2a/IgG1 ratio in immune response triggered by recombinant protein vaccines administered 
intramuscularly, indicate a mixed Th1/Th2 immune response stimulation. 
In the present study the two types of vaccines induced an effective immune response, where both 
Th1 and Th2 types were stimulated, except for pDNA vaccine administered orally. It was expected 
that a major IgG2a/IgG1 rate would result from pDNA vaccination, but it was the protein-based 
vaccines that induced higher IgG levels. Nevertheless, both vaccines were capable of inducing both 
Th1 and Th2 immune responses, being the highest responses triggered by the proteins given by i.m. 
route.  
After i.m. administration chitosan nanoparticles slowly release the encapsulated pDNA, 
promoting a prolonged presentation of the antigens to APC cells. Moreover, the results demonstrate 
that these nanoparticles are efficient in stimulating a lasting immune response against H. pylori 
antigens, and act as a reservoir of the antigens since there was a prolonged immune response over 15 
weeks. This is also due to their immunological adjuvant properties and immunogenic characteristics, 
such as mucoadhesiveness and penetration enhancing activity into host cells. 
However, oral vaccination with nanoencapsulated pDNA did not induce a strong immune response, 
probably due to incapacity of penetrate the stomach mucosa or resist to the acid pH and enzymes 
present in the stomach (as aforementioned). 
In general, it seems that CS particulate systems allowed the development of continuous and 
sustained immune response when compared with antigen solutions. Besides, both recombinant 
proteins and pDNA strategies for immunization showed promising results with a consistent Th1/Th2 
immune response emerging as new approaches from vaccination against H. pylori. In that way, more 
studies will have to be done for increasing the efficacy of the delivery systems and selecting the best 
administration route. A heterologous immunization seems to be a potential approach since 
recombinant proteins showed higher capacity to stimulate both Th1 and Th2 responses by both routes 
of administration and pDNA showed the ability to induce mixed responses after i.m. administration. It 
also shows that the choice of routes to deliver plasmid DNA for obtaining higher and efficacious 
immunogenicity of the expressed antigens is rather restricted (Bohm et al., 1998). 
  
3. Results and Discussion 
53 
 
3.2.2.1. Local IgA immune responses 
 
As H. pylori infects their hosts by oral route and establishes an infection in the stomach, it was 
thought that oral immunization could provide a fist line of defence. Oral immunization was thought for 
mucosal immunity stimulation in order to induce a stronger systemic immune response against H. 
pylori, to confer a more protective immunity. 
Other studies showed  that local secretory IgA (sIgA) production at mucosal level, could be very 
important for establishing a first line of defence at the mucosal surface of the stomach in order to 
stimulate lymphocytes proliferation that will promoting the production of more specific IgA blocking 
H. pylori adhesion (Vajdy et al., 2003; Moss et al., 2011). The inhibition of bacterial adhesion may 
contribute to eliminate the infection. On the other hand, mucosal immunization will also promote 
systemic humoral and cellular immunity (Kabir, 2007; Zhou et al., 2009; Moss et al., 2011; Figueiredo 
et al., 2012a). 
To assess the success of the mucosal immunization, the sIgA levels present in intestines of 
vaccinated BALB/c mice, were evaluated (Figure 3.2.2.1.1).  
 
 
Figure 3.2.2.1.1 - sIgA levels in intestine homogenates of mice immunised by i.m. and oral route 
with:  G1 – nanoencapsulated pDNA by oral route; G2 – free pDNA in solution by oral route; G3 – 
nanoencapsulated recombinant protein by oral route; G4 – free recombinant protein in solution by oral 
route; G5 – nanoencapsulated pDNA by i.m. route; G6 – free pDNA in solution by i.m. route; G7 – 
nanoencapsulated recombinant protein by i.m. route; G8 – free recombinant protein in solution by i.m. 
route (n=5; mean ± SD). 
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As expected, results showed a high level of local immunization by oral route, when compared 
with negative control (G9). Nanoencapsulated pDNA administered orally showed the greatest level of 
SIgA stimulation, showing a significant difference (p=0.0079) from the negative control. On the other 
hand, pDNA in solution also stimulated SIgA, but at levels much lower than those elicited by 
nanoencapsulated pDNA, despite showing no significant difference (p=0.0556).  
Encapsulated recombinant proteins administered orally also induced high level of sIgA, when 
compared with negative control (p=0.0079), and present significant differences (p=0.0079) when 
compared with immunizations with recombinant proteins in solution (G4) by oral route. This indicates 
these antigens are not capable of inducing an effective immunity without the presence of an adjuvant 
or a delivery system capable to protect them from degradation and to increase immunogenicity and 
uptake by the host cells. Hence, chitosan nanoparticles are essential for efficient oral antigen 
presentation at epithelial cells, due to their capacity of adhesion to epithelium leading prolonged 
exposures to APC. Free recombinant proteins delivery orally (G4), present the same mucosal response 
that the group immunized with empty chitosan nanoparticles (G9). All other groups showed very low 
levels of sIgA, since they were not administered via mucosal and then induced no mucosal response, 
as expected. 
Therefore, locally produced sIgA is thought to be important to prevent and control this endemic 
disease, mainly in their route of entry, being complemented by systemic immune response (Kabir, 
2007). Some studies have shown the protective effect of mucosal immunization against H. Pylori, 
eradicating previous Helicobacter infections in mice (Vajdy et al., 2003), providing eradication of 
ongoing infections and evidence that re-infection following oral vaccination could be prevented. As in 
this study, no cellular immunity was detected after oral immunizations, indicates that this route of 
immunization is not inducing the type of immunity found in mice prophylactically immunized. So, a 
positively approach in this study, could be heterologous immunization with pDNA administered orally 
and recombinant proteins administered intramusculary. The responses generated by heterologous 
vaccination may show whether there are indeed differences between the responses generated by oral 
vaccination and heterologous oral / i.m. vaccine. 
The mainly difference that distinguishes our study, which confers advantages, is the fact that we 
use a vaccine comprising different antigens from different strains of H. pylori which will provide 
protection against a greater number of strains. 
 
 
3.2.2.2.  Cytokine production 
 
The T lymphocytes expressing CD4+ at cell surface, stimulated by MHC II, release different 
types of cytokines. Through analysis of which type of cytokines is produced, we can infer what type of 
response is being stimulated. So T helper cells were divided according to the type of cytokines 
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secreted: Th1 cells mainly secret IL-2 and IFN-γ, stimulating a cellular immune response promoting 
synthesis of IgG2a, while Th2 cells express IL-4, IL-5, IL-6, IL-10 and IL-13, stimulating a humoral 
immune response promoting secretion of IgG1 (Florindo et al., 2009; Figueiredo et al., 2012a; Wilson 
and Crabtree, 2007)  
As seen before, CD4+ T cells are essential for protection against H. pylori. During H. pylori 
infection, only Th1 immune response is stimulated a cellular response being ineffective in eradicating 
this infection. Studies suggest that an induction of a well-equilibrate and balance Th1/Th2 immune 
response together with mucosal immunity, could eradicate the infection and confer protection (Vajdy 
et al., 2003; Strugnell and Wijburg, 2010; Moss et al., 2011).  
In order to understand what type of immune response is actually induced by each vaccine 
formulation, the supernatants of cells extracted from the spleens of immunized mice were collected to 
quantify the cytokines produced in response to vaccines administered (Figure 3.2.2.2.1). Group 2 
immunized with pDNA in solution by oral route and Group 4 immunized with recombinant proteins in 
solution by oral route were not analysed. 
 
 
 
Figure 3.2.2.2.1 - Cytokine levels after splenocyte stimulation with H. pylori antigens (Note: G2 and 
G4 were not analysed). Columns with a (*) show significant differences (p<0.05) from the negative 
control (G9).  
 
Figure 3.2.2.2.1 shows that all the immunized mice groups developed a humoral immune 
response, due the high levels of IL-10, including group 9 which is the negative control immunized 
with empty nanoparticles. This indicates that the nanoparticulate system used is highly immunogenic 
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and could induce both humoral and cellular responses, as shown by the high levels of IL-2 and IL-10, 
thus confirming the previous reports from our research group (Cadete et al., 2012; Figueiredo et al., 
2012b).  
On the other hand, immune response resulting from oral vaccination did not show significant 
differences between Group 1 (nanoencapsulated pDNA) and Group 3 (nanoencapsulated recombinant 
protein), stimulating essentially a Th2 polarized response, due to the chitosan nanoparticules. 
The pDNA administered by i.m. route, either encapsulated or nonencapsulated, showed 
significant differences (p<0.05) among them, with free pDNA (G6) inducing a higher balanced 
immune response than encapsulated pDNA.  Group 6 showed significant differences in IFN-γ when 
compared to negative control (G9) (p=0.0079), proved to be more efficient in induce a stronger and 
balanced immune response. Group 7, immunized with encapsulated proteins by i.m. route, induced a 
balanced Th1/Th2 immune response by IgGs isotypes levels, in agreement with high and equilibrate 
levels of cytokines. Significant differences were observed in IFN-γ (p=0.0079) and IL-2 (p=0.0079) 
when compared to negative control. 
These results indicate that both antigens were able to induce an immune response by i.m. route, 
stimulate both Th1 and Th2 responses, which is in line with the levels of specific IgGs previously 
analysed (Section 3.2.2.). 
These results substantiate that the epitope-based vaccine described here, should support the 
immune system fighting against H. pylori infections and prevent H. pylori colonization and infection. 
 
 
3.3.  Helicobacter pylori agglutinations assays 
 
Sera from the last sampling of vaccination groups were tested against a total of nine H. pylori 
strains. The presumptive results of the agglutination tests are shown in Table 3.3.1. 
The aim of this approach is to verify if antibodies present in sera of immunized mice (section 
2.2.2.) specifically reacted with different, clinically relevant, H. pylori strains.  
Maeland et al. (1997) demonstrated that almost all H. pylori strains used show strong 
agglutination with at least one of the two sera from infected mice. But a small percentage of H. pylori 
strains showed autoagglutination. These tests are based on the variability of the surface-localized 
antigens of each H. pylori strain, which function as agglutinogens in presence of specific antibodies 
against specific H. pylori strain antigens. These results allow identifying the majority of cultured H. 
pylori strains by agglutination testing (Maeland et al., 1997). 
It should be noticed that this is a presumptive test and that as in all agglutination tests, it is very 
difficult to conclude if there was bacterial agglutination with sera tested, due to the negative control 
(H. pylori strain only) that almost always stays with a cloudy appearance and small agglomerates with 
bleached centre. Even with sera from negative control mice (immunized with empty nanoparticles – 
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G9) it was difficult to understand whether or not there was agglutination of bacteria. This may be due 
to the fact that H. pylori cultures may form a biofilm when in suspension (Vale and Vitor, 2010).   
 
Table 3.3.1 – Results from agglutination tests with H. pylori bacterial suspension against sera of 
immunized mice. (+) indicates positive results; (-) indicates negative results where no agglutination is 
observed; (?) indicates inconclusive results. 
Sera groups G1 G2 G3 G4 G5 G6 
Strains Dilutions 1:10 1:40 1:10 1:40 1:10 1:40 1:10 1:40 1:10 1:40 1:10 1:40 
B1A - - - - - - - - - - - - 
B6A + + ? ? + + + + + + + + 
B8A + + + + - - ? ? - - + + 
BAPOUI + + + + + + + ? ? ? + + 
P1 - - - - - - - - - - - - 
26695 + + + + ? ? + + + + + + 
HS11 + - + + + - - + + + - ? 
B45 + + + + + + + + + + + + 
B3C - - - - - - - - - - - - 
 
Strains/Dilutions 
G7 G8  G9 
1:10 1:40 1:10 1:40 1:10 1:40 
B1A - - - - - - 
B6A + + + +  + + 
B8A + + + +  + + 
BAPOUI + + + +  + + 
P1 + - - -  - - 
26695 + + + +  + + 
HS11 + + + +  + - 
B45 + ? ? +  + + 
B3C - - - -  - - 
 
In B1A and B3C (Table 3.3.1) no agglutination was observed with any sera used, indicating the 
sera from immunized mice do not contain antibodies against the antigens present in these strains. In all 
of the others strains agglutinations were observed with all the sera of immunized mice, even with the 
sera from negative control groups (G9).  
These agglutination tests based on visual observation are rather subjective and presumptive, 
depending largely on operator interpretation. So, in order to confirm if the antibodies present in sera of 
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immunized mice effectively react with antigens of different H. pylori strains, Western Blot must be 
performed in future studies. 
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Despite decades of research, the immune response to H. pylori and the correlation of successful 
immunity necessary for protection and eradication of H. pylori remain poorly understood. The 
immunity generated after H. pylori infections always show inadequate ability in eradicating the 
infections and due to the continued process of inflammation the infection may progress to chronic 
gastritis, peptic ulcers or gastric cancer (Algood and Cover, 2006; Wilson and Crabtree, 2007; Zhou et 
al., 2009; Moss et al., 2011).  
Current therapies used in treatment of H. pylori infections comprise combination of antibiotics in 
conjunction with proton pump inhibitor, leading to several problems such as re-infections, side effects 
and antimicrobial resistance. Accordingly, it is unanimous that therapy-based vaccines anti-H. pylori 
are the best approach to eradicate the infection and prevent new infections. 
Several vaccine approaches are being made, using a wide range of strategies such as the use of 
whole cell lysates, or specific recombinant antigens, but previous studies in animal models provided 
poor or no immunity against H. pylori (Kabir, 2007; Zhou et al., 2009; Liu et al., 2011). So a multi-
epitope based vaccine was constructed based on most common virulence factors among H. pylori 
strains and on most virulence antigens essential for successful infection by H. pylori. The antigens 
epitopes chosen were cloned into two different plasmid vectors so that recombinant protein is 
expressed in both prokaryotic and eukaryotic cells. In order to formulate pDNA- and recombinant 
proteins-based vaccine, the recombinant proteins were produced in E. coli transformed cells with 
recombinant pQE30 plasmid and then purified through a nickel-affinity chromatography column. The 
purification process was achieved successfully confirmed by SDS-PAGE and Western Blot, protein 
has been purified either as soluble or insoluble. However 6T protein does not need to be soluble to 
retain its function, it can be used directly as antigen since it retains its immunogenicity. The pDNA 
was also extracted from E. coli transformed cells with recombinant pVAX plasmid and then purified 
through Mega QIAfilter Plasmid purification kit (QIAGEN Inc., German). The pDNA was 
successfully purified, without any other components as shown by electrophoretic analysis. The two 
antigens, pDNA and the recombinant proteins, were assessed as a therapeutic vaccine in a mouse 
model. 
The assessment of systemic titres of specific IgG, IgG1 and IgG2a antibodies reveals a better 
immune response after i.m. immunization. Moreover, recombinant protein encapsulated in 
nanoparticles present a high and more balanced immune response than that obtained with encapsulated 
pDNA. Cytokine levels support the evidence for a more relevant immune response after i.m. 
immunization, which is in agreement with IgG titres. The chitosan nanoparticles also showed high 
levels of IL-2 and IL-10 that confirm the immunological adjuvant properties of these nanoparticles. 
Intramuscular immunization with encapsulated proteins results in a well-balanced immune response 
confirmed by the presence of the characteristic Th1/Th2 cytokines and specific IgG titres. 
The oral vaccination shows a higher stimulation of sIgA, which can be a good result for 
controlling the infection and preventing the colonization of the gastric mucosa. In order to confirm this 
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findings a challenge assay with H. pylori will be needed to study if there is colonization and infection 
or not, after oral vaccination. 
The finding that H. pylori infections stimulate a Th1-polarized immune response that showed 
ineffective in fighting against these infections, suggest that a balanced Th1/Th2 immune response are 
important to mediate an effective immunity against H. pylori in order to protect and eradicate 
infections. On the other hand, there is consensus of our research group that a mucosal immunity could 
confer a fist line of defence at mucosal level leading to prevent new infections. So, , we developed a 
multi-epitope pDNA- and recombinant protein-based vaccine that showed an efficient induction of 
both Th1 and Th2 response, with high IgG1 and IgG2a titres together with high cytokine levels, 
mainly by i.m. route. On the other hand, oral vaccination induced high levels of SIgA indicating an 
effective stimulation of mucosal immunity, conferring protection at this level. Duo to the high 
stimulation of systemic immunity by i.m. immunization and high stimulation of mucosal immunity by 
oral immunization, a DNA-prime/peptide boost could be a good approach for future immunization 
studies.  
In conclusion, this study shows that a multi-epitope vaccine is a promising candidate for the 
development of an adequate immunity against H. pylori infections. Ongoing studies will evaluate the 
best routes of immunization and the best approach to improve protective immunity. Ultimately, we 
hope that these studies will lead to a therapeutic and prophylactic effective vaccine for human use. 
Following this work, it would be interesting, in future studies, to compare the responses generated 
by an oral vaccination and a heterologous oral/ i.m. vaccination, in order to infer what is the best 
approach, since our objective was the development of a vaccine for oral administration, due to its 
advantages in administration, security, storage and stability. It would be also interesting to evaluate the 
protective immunity conferred by this vaccine, by performing an experimental infection in immunized 
animals. After proven successful immunization of mice, the next step would be to evaluate the 
potential of the vaccine in prime H. pylori hosts, the humans. 
Agglutination slide tests made showed agglutination of some H. pylori strains with most sera 
from immunized mice, but also agglutination of certain strains of H. pylori with sera from immunized 
mice with empty nanoparticles without the presence of antigens. Agglutination slide tests will have to 
be optimized in order to obtain more concrete and reliable results and must be confirmed by Western 
Blot to confirm the presence of anti-H. pylori antibodies in sera of immunized mice. 
 
5. References 
63 
 
 
 
 
 
 
5. References 
  
  
 
1 
5. References 
65 
 
Aebischer T, Meyer TF, Andersen LP. 2010. Inflammation, immunity, and vaccines for Helicobacter. 
Helicobacter 15 Suppl 1:21-28. 
Algood HM, Cover TL. 2006. Helicobacter pylori persistence: an overview of interactions between H. 
pylori and host immune defenses. Clin Microbiol Rev 19:597-613. 
Amieva MR, El-Omar EM. 2008. Host-bacterial interactions in Helicobacter pylori infection. 
Gastroenterology 134:306-323. 
Arnau J, Lauritzen C, Petersen GE, Pedersen J. 2011. Reprint of: Current strategies for the use of 
affinity tags and tag removal for the purification of recombinant proteins. Protein Expression 
and Purification 48:1-13. 
Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J. 2010. Enhancing oral vaccine potency by targeting 
intestinal M cells. PLoS Pathog 6:e1001147. 
Backert S, Tegtmeyer N, Selbach M. 2010. The versatility of Helicobacter pylori CagA effector 
protein functions: The master key hypothesis. Helicobacter 15:163-176. 
Begue RE, Sadowska-Krowicka H. 2010. Protective efficacy of recombinant urease B and aluminum 
hydroxide against Helicobacter pylori infection in a mouse model. FEMS Immunol Med 
Microbiol 60:142-146. 
Bohm W, Mertens T, Schirmbeck R, Reimann J. 1998. Routes of plasmid DNA vaccination that prime 
murine humoral and cellular immune responses. Vaccine 16:949-954. 
Boyoglu S, Vig K, Pillai S, Rangari V, Dennis VA, Khazi F, Singh SR. 2009. Enhanced delivery and 
expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. 
Nanomedicine 5:463-472. 
Cadete A, Figueiredo L, Lopes R, Calado CC, Almeida AJ, Goncalves LM. 2012. Development and 
characterization of a new plasmid delivery system based on chitosan-sodium deoxycholate 
nanoparticles. Eur J Pharm Sci 45:451-458. 
Calvet X, Lehours P, Lario S, Megraud F. 2010. Diagnosis of Helicobacter pylori infection. 
Helicobacter 15 Suppl 1:7-13. 
Carlsohn E, Nystrom J, Bolin I, Nilsson CL, Svennerholm AM. 2006. HpaA is essential for 
Helicobacter pylori colonization in mice. Infect Immun 74:920-926. 
Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A. 1996. 
cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-
associated virulence factors. Proc Natl Acad Sci U S A 93:14648-14653. 
Chadwick S, Kriegel C, Amiji M. 2010. Nanotechnology solutions for mucosal immunization. Adv 
Drug Deliv Rev 62:394-407. 
Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, Massone A, Papini E, Xiang Z, 
Figura N, et al. 1993. Molecular characterization of the 128-kDa immunodominant antigen of 
Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S 
A 90:5791-5795. 
5. References 
66 
 
Crew KD, Neugut AI. 2006. Epidemiology of gastric cancer. World J Gastroenterol 12:354-362. 
Del Giudice G, Malfertheiner P, Rappuoli R. 2009. Development of vaccines against Helicobacter 
pylori. Expert Rev Vaccines 8:1037-1049. 
Dubois A. 2007. Intracellular Helicobacter pylori and gastric carcinogenesis: an "old" frontier worth 
revisiting. Gastroenterology 132:1177-1180. 
Figueiredo L, Cadete A, Goncalves LM, Corvo ML, Almeida AJ. 2012a. Intranasal immunisation of 
mice against Streptococcus equi using positively charged nanoparticulate carrier systems. 
Vaccine. 
Figueiredo L, Calado CCR, Almeida AJ, Goncalves LMD. 2012b. Protein and DNA nanoparticulate 
multiantigenic vaccines against H. pylori: in vivo evaluation. Bioengineering (ENBENG), 
2012 2st Portuguese Meeting in Portuguese chapter of IEEE EMBS, Rectory of the University 
of Coimbra. 
Florindo HF, Pandit S, Goncalves LM, Alpar HO, Almeida AJ. 2009. New approach on the 
development of a mucosal vaccine against strangles: Systemic and mucosal immune responses 
in a mouse model. Vaccine 27:1230-1241. 
Florindo HF, Pandit S, Goncalves LM, Alpar HO, Almeida AJ. 2010. Surface modified polymeric 
nanoparticles for immunisation against equine strangles. Int J Pharm 390:25-31. 
Gonçalves LMD, Cadete A, Figueiredo L, Calado CCR, Almeida AJ. 2011. Biodegradable 
nanoparticles of alginate and chitosan as non-viral DNA oral delivery system. Bioengineering 
(ENBENG), 2011 1st Portuguese Meeting in pp.1-4, 1-4 March 2011. (doi: 
10.1109/ENBENG.2011.6026051). 
Han ZS, Li QW, Zhang ZY, Xiao B, Gao DW, Wu SY, Li J, Zhao HW, Jiang ZL, Hu JH. 2007. High-
level expression of human lactoferrin in the milk of goats by using replication-defective 
adenoviral vectors. Protein Expr Purif 53:225-231. 
Ingolotti M, Kawalekar O, Shedlock DJ, Muthumani K, Weiner DB. 2010. DNA vaccines for 
targeting bacterial infections. Expert Rev Vaccines 9:747-763. 
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer 
J Clin 61:69-90. 
Kabir S. 2007. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12:89-102. 
Kawai T, Akira S. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection 
and immunity. Immunity 34:637-650. 
Khalifa MM, Sharaf RR, Aziz RK. 2010. Helicobacter pylori: a poor man's gut pathogen? Gut Pathog 
2:2. 
Kindt TJ, Goldsby RA, Osborne BA, Kuby J. 2006. Kuby immunology. New York, N.Y. ; 
Basingstoke: W.H. Freeman. 
Konturek PC, Konturek SJ, Brzozowski T. 2009. Helicobacter pylori infection in gastric 
cancerogenesis. J Physiol Pharmacol 60:3-21. 
5. References 
67 
 
Krieg RC, Dong Y, Schwamborn K, Knuechel R. 2005. Protein quantification and its tolerance for 
different interfering reagents using the BCA-method with regard to 2D SDS PAGE. J 
Biochem Biophys Methods 65:13-19. 
Kusters JG, van Vliet AH, Kuipers EJ. 2006. Pathogenesis of Helicobacter pylori infection. Clin 
Microbiol Rev 19:449-490. 
Kutzler MA, Weiner DB. 2008. DNA vaccines: ready for prime time? Nat Rev Genet 9:776-788. 
Letley DP, Atherton JC. 2000. Natural diversity in the N terminus of the mature vacuolating cytotoxin 
of Helicobacter pylori determines cytotoxin activity. J Bacteriol 182:3278-3280. 
Lima V, Rabenhorst S. 2009. Genes Associados à Virulência de Helicobacter Pylori. Revista 
Brasileira de Cancerologia 55(4):389-396. 
Liu KY, Shi Y, Luo P, Yu S, Chen L, Zhao Z, Mao XH, Guo G, Wu C, Zou QM. 2011. Therapeutic 
efficacy of oral immunization with attenuated Salmonella typhimurium expressing 
Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model. Vaccine 29:6679-
6685. 
Lundstrom AM, Blom K, Sundaeus V, Bolin I. 2001. HpaA shows variable surface localization but the 
gene expression is similar in different Helicobacter pylori strains. Microb Pathog 31:243-253. 
Maeland JA, Piene M, Muller LI. 1997. Feasibility of Helicobacter pylori identification by a slide 
agglutination test. APMIS 105:157-160. 
Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. 1985. Attempt to fulfil Koch's postulates for 
pyloric Campylobacter. Med J Aust 142:436-439. 
McClain MS, Cao P, Iwamoto H, Vinion-Dubiel AD, Szabo G, Shao Z, Cover TL. 2001. A 12-amino-
acid segment, present in type s2 but not type s1 Helicobacter pylori VacA proteins, abolishes 
cytotoxin activity and alters membrane channel formation. J Bacteriol 183:6499-6508. 
Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers AB, Martin W, De Groot AS. 2011. 
HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. 
Vaccine 29:2085-2091. 
Neutra MR, Kozlowski PA. 2006. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 
6:148-158. 
Olaofe OA, Burton SG, Cowan DA, Harrison STL. 2010. Improving the production of a thermostable 
amidase through optimising IPTG induction in a highly dense culture of recombinant 
Escherichia coli. Biochem Eng J 52:19-24. 
Oleastro M, Cordeiro R, Ferrand J, Nunes B, Lehours P, Carvalho-Oliveira I, Mendes AI, Penque D, 
Monteiro L, Megraud F, Menard A. 2008. Evaluation of the clinical significance of homB, a 
novel candidate marker of Helicobacter pylori strains associated with peptic ulcer disease. J 
Infect Dis 198:1379-1387. 
Peek RM, Jr., Fiske C, Wilson KT. 2010. Role of innate immunity in Helicobacter pylori-induced 
gastric malignancy. Physiol Rev 90:831-858. 
5. References 
68 
 
PicoGreen® dsDNA Quantitation Reagent and Kits PI, Molecular Probes, 
http://tools.invitrogen.com/content/sfs/manuals/mp07581.pdf. 
Ramos CR, Abreu PA, Nascimento AL, Ho PL. 2004. A high-copy T7 Escherichia coli expression 
vector for the production of recombinant proteins with a minimal N-terminal His-tagged 
fusion peptide. Braz J Med Biol Res 37:1103-1109. 
Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA, Eshagh Hosseini M, Atherton JC. 
2007. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, 
is associated with gastric cancer. Gastroenterology 133:926-936. 
Schubert ML, Peura DA. 2008. Control of gastric acid secretion in health and disease. 
Gastroenterology 134:1842-1860. 
Shahiwala A, Vyas TK, Amiji MM. 2007. Nanocarriers for systemic and mucosal vaccine delivery. 
Recent Pat Drug Deliv Formul 1:1-9. 
Shedlock DJ, Weiner DB. 2000. DNA vaccination: antigen presentation and the induction of 
immunity. J Leukoc Biol 68:793-806. 
Sijun H, Yong X. 2009. Helicobacter pylori vaccine: mucosal adjuvant & delivery systems. Indian J 
Med Res 130:115-124. 
Singer VL, Jones LJ, Yue ST, Haugland RP. 1997. Characterization of PicoGreen reagent and 
development of a fluorescence-based solution assay for double-stranded DNA quantitation. 
Anal Biochem 249:228-238. 
Sorensen HP, Mortensen KK. 2005. Advanced genetic strategies for recombinant protein expression in 
Escherichia coli. J Biotechnol 115:113-128. 
Stadler J, Lemmens R, Nyhammar T. 2004. Plasmid DNA purification. J Gene Med 6 Suppl 1:S54-66. 
Strugnell RA, Wijburg OLC. 2010. The role of secretory antibodies in infection immunity. 
wwwnaturecom/reviews/micro 8:656-667. 
Suerbaum S, Michetti P. 2002. Helicobacter pylori infection. N Engl J Med 347:1175-1186. 
Tegtmeyer N, Wessler S, Backert S. 2011. Role of the cag-pathogenicity island encoded type IV 
secretion system in Helicobacter pylori pathogenesis. FEBS J 278:1190-1202. 
Teich A, Lin HY, Andersson L, Meyer S, Neubauer P. 1998. Amplification of ColE1 related plasmids 
in recombinant cultures of Escherichia coli after IPTG induction. J Biotechnol 64:197-210. 
Terpe K. 2003. Overview of tag protein fusions: from molecular and biochemical fundamentals to 
commercial systems. Appl Microbiol Biotechnol 60:523-533. 
Triccas JA, Parish T, Britton WJ, Gicquel B. 1998. An inducible expression system permitting the 
efficient purification of a recombinant antigen from Mycobacterium smegmatis. FEMS 
Microbiol Lett 167:151-156. 
Vajdy M, Singh M, Ugozzoli M, Briones M, Soenawan E, Cuadra L, Kazzaz J, Ruggiero P, Peppoloni 
S, Norelli F, del Giudice G, O'Hagan D. 2003. Enhanced mucosal and systemic immune 
5. References 
69 
 
responses to Helicobacter pylori antigens through mucosal priming followed by systemic 
boosting immunizations. Immunology 110:86-94. 
Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M. 2004. Mucosal adjuvants and 
delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 82:617-
627. 
Vale FF, Vitor JM. 2010. Transmission pathway of Helicobacter pylori: does food play a role in rural 
and urban areas? Int J Food Microbiol 138:1-12. 
Velin D, Michetti P. 2010. Advances in vaccination against Helicobacter pylori. Expert Rev 
Gastroenterol Hepatol 4:157-166. 
Vitoriano I, Rocha-Goncalves A, Carvalho T, Oleastro M, Calado CR, Roxo-Rosa M. 2011. Antigenic 
diversity among Portuguese clinical isolates of Helicobacter pylori. Helicobacter 16:153-168. 
Voland P, Hafsi N, Zeitner M, Laforsch S, Wagner H, Prinz C. 2003. Antigenic properties of HpaA 
and Omp18, two outer membrane proteins of Helicobacter pylori. Infect Immun 71:3837-
3843. 
Walker JM. 2009. The protein protocols handbook. New York, N.Y.: Humana Press. 
Weng YP, Hsu FC, Yang WS, Chen HP. 2006. Optimization of the overexpression of glutamate 
mutase S component under the control of T7 system by using lactose and IPTG as the 
inducers. Enzyme Microb Tech 38:465-469. 
Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. 
2009. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 98:1278-
1316. 
Wilson KT, Crabtree JE. 2007. Immunology of Helicobacter pylori: insights into the failure of the 
immune response and perspectives on vaccine studies. Gastroenterology 133:288-308. 
Zhang HY, Sun SH, Guo YJ, Zhou FJ, Chen ZH, Lin Y, Shi K. 2003. Immune response in mice 
inoculated with plasmid DNAs containing multiple-epitopes of foot-and-mouth disease virus. 
Vaccine 21:4704-4707. 
Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, Guo G, Li HX, Zou QM. 2009. Therapeutic efficacy of 
a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine 
27:5013-5019. 
 
  
 
